VIOLIN: Vaccine Investigation and Online Information Network

Dengue Virus

Table of Contents

General Information
Vaccine Related Pathogen Genes
1. 18H6 synthetic E protein (Protective antigen)
2. E from Dengue virus 1 (Protective antigen)
3. E from Dengue virus 3 (Protective antigen)
4. E from Dengue virus 4 (Protective antigen)
5. E protein from Dengue Virus 2 (Protective antigen)
6. M protein (Protective antigen)
7. NS1 (Protective antigen)
8. POLY (Protective antigen)
9. POLY (Protective antigen)
10. POLY (Protective antigen)
11. POLY (Protective antigen)
12. prM from Dengue virus 1 (Protective antigen)
13. prM from Dengue virus 2 (Protective antigen)
14. prM from Dengue virus 3 (Protective antigen)
15. prM from Dengue virus 4 (Protective antigen)
Vaccine Related Host Genes
1. Il12a
Vaccine Information
References

I. General Information

1. NCBI Taxonomy ID:

12637

2. Disease:

Dengue Fever

3. Introduction

Dengue (DEN) viruses belong to the family Flaviviridae and consist of four distinct antigenic serotypes, DEN1–4. DEN viruses are transmitted primarily by the mosquito Aedes aegypti and cause over 100 million human infections per year, which are manifested clinically by either DEN fever (DF), a self-limited febrile illness, or more severe DEN hemorrhagic fever/DEN shock syndrome (DHF/DSS) usually with a mortality that ranges from 1 to 5%. Epidemic DF/DHF has been emerging as one of the most important global public health problems in the tropical and subtropical countries at the beginning of the 21st century. It is imperative to support research on the development of new mosquito control technology and on the establishment of preventive strategies, including the development of effective and safe dengue vaccines (Liu et al., 2006).

4. Microbial Pathogenesis

During the feeding of mosquitoes on humans, DENV is presumably injected into the bloodstream, with spillover in the epidermis and dermis, resulting in infection of immature Langerhans cells (epidermal dendritic cells [DC]), and keratinocytes. Infected cells then migrate from site of infection to lymph nodes, where monocytes and macrophages are recruited, which become targets of infection. Consequently, infection is amplified and virus is disseminated through the lymphatic system. As a result of this primary viremia, several cells of the mononuclear lineage, including blood-derived monocytes, myeloid DC, and splenic and liver macrophages are infected (Martina et al., 2009).

5. Host Ranges and Animal Models

Dengue is transmitted to humans by Aedes mosquitoes, mainly Aedes aegypti. There is no animal model of disease that mimics the disease in humans (Martina et al., 2009).

6. Host Protective Immunity

In most acute virus infection models, the presence of antibodies, both neutralizing and nonneutralizing, correlates with control, elimination, and eventually protection (Martina et al., 2009).

II. Vaccine Related Pathogen Genes

1. 18H6 synthetic E protein

Gene Name : 18H6 synthetic E protein
Sequence Strain (Species/Organism) : synthetic construct
NCBI Nucleotide GI : 73915390
NCBI Protein GI : 73915391
Protein Accession : AAZ92557.1
Other Database IDs : CDD:279241
CDD:280922
CDD:213897
Taxonomy ID : 32630
Gene Strand (Orientation) : ?
Protein Name : chimeric Dengue envelope antigen 18H6
Protein pI : 7.33
Protein Weight : 46583.77
Protein Length : 549
Protein Note : derived from Dengue virus

DNA Sequence : Show Sequence

>gi|73915390|gb|DQ158253.1| Synthetic construct chimeric Dengue envelope antigen 18H6 mRNA, partial cds
ATGGTGGTGATCTTCATCCTGCTGATGCTGGTGACCCCCTCCATGACAATGAGGTGCGTGGGCGTGGGCA
ACAGGGACTTCGTGGAGGGCCTGAGCGGCGCCACCTGGGTGGACGTGGTGCTGGAGCACGGCGGCTGCGT
GACCACCATGGCCAAGAACAAGCCCACCCTGGACTTCGAGCTGATCAAGACCACCGCCAAGGAGGTGGCC
CTGCTGAGGACCTACTGCATCGAGGCCAGCATCAGCAACATCACCACCGCCACCAGGTGCCCCACCCAGG
GCGAGGCCATCCTGCCCGAGGAGCAGGACCAGAACTACGTGTGCAAGCACACCTACGTGGACAGGGGCTG
GGGCAACGGCTGCGGCCTGTTCGGCAAGGGCAGCCTGGTGACCTGCGCCAAGTTCACCTGCAAGAAGAAC
ATGGAGGGCAACATCGTGCAGCCCGAGAACCTGGAGTACACCATCGTGATCACCCCCCACACCGGCGACC
AGCACCAGGTGGGCAACGACACCCAGGGCGTGACCGTGGAGATCACCCCCCAGGCCAGCACCGTGGAGGC
CATCCTGCCCGAGTACGGCACCCTGGGCCTGGAGTGCAGCCCCAGGACTGGCCTGGACTTCAACAGGGTG
GTGCTGCTGACCATGAAGAAGAAGAGCTGGCTGGTGCACAAGCAGTGGTTCCTGGACCTGCCCCTGCCCT
GGACCGCCGGCGCCGACACCAGCGAGGTGCACTGGAACCACAAGGAGAGGATGGTGACCTTCAAGAACGC
CCACGCCAAGAGGCAGGACGTGACCGTGCTGGGCAGCCAGGAGGGCGCCATGCACAGCGCCCTGGCCGGC
GCCACCGAGATCCAGATGAGCAGCGGCAACCTGCTGTTCACCGGCCACCTGAAGTGCAGGCTGAAGATGG
ACAAGCTGCAGCTGAAGGGCGTGAGCTACGTGATGTGCACCGGCAGCTTCAAGCTGGAGAAGGAGGTGGC
CGAGACCCAGCACGGCACCGTGCTGGTGCAGGTGAAGTACGAGGGCACCGACGCCCCCTGCAAGATCCCC
TTCAGCACCGAGGACGGCCAGGGCAAGGCCCACAACGGCAGGCTGATCACCGTGAACCCCATCGTGATCG
ACAAGGAGAAGCCCGTGAACATCGAGCTGGAGCCCCCCTTCGGCGAGAGCTACATCGTGGTGGGCGCCGG
CGAGAAGGCCCTGAAGCTGAGCTGGTTCAAGAAGGGCAGCAGCATCGGCAAGATGTTCGAGGCCACCGCC
AGGGGCGCCAAGAGGATGGCCATCCTGGGCGAGACCGCCTGGGACTTCGGCAGCGTGGGCGGCCTGCTGA
CCAGCCTGGGCAAGGCCGTGCACCAGGTGTTCGGCGCCATCTACGGCGCC

Protein Sequence : Show Sequence

>AAZ92557.1 chimeric Dengue envelope antigen 18H6, partial [synthetic construct]
MVVIFILLMLVTPSMTMRCVGVGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDFELIKTTAKEVA
LLRTYCIEASISNITTATRCPTQGEAILPEEQDQNYVCKHTYVDRGWGNGCGLFGKGSLVTCAKFTCKKN
MEGNIVQPENLEYTIVITPHTGDQHQVGNDTQGVTVEITPQASTVEAILPEYGTLGLECSPRTGLDFNRV
VLLTMKKKSWLVHKQWFLDLPLPWTAGADTSEVHWNHKERMVTFKNAHAKRQDVTVLGSQEGAMHSALAG
ATEIQMSSGNLLFTGHLKCRLKMDKLQLKGVSYVMCTGSFKLEKEVAETQHGTVLVQVKYEGTDAPCKIP
FSTEDGQGKAHNGRLITVNPIVIDKEKPVNIELEPPFGESYIVVGAGEKALKLSWFKKGSSIGKMFEATA
RGAKRMAILGETAWDFGSVGGLLTSLGKAVHQVFGAIYGA

Molecule Role : Protective antigen
Related Vaccine(s): Dengue virus DNA vaccine sABC encoding prM and E , Dengue virus DNA vaccine sB encoding E

2. E from Dengue virus 1

Gene Name : E from Dengue virus 1
Sequence Strain (Species/Organism) : Dengue virus 1
NCBI Protein GI : 148372385
Other Database IDs : CDD:279241
CDD:332896
CDD:213392
CDD:213897
Taxonomy ID : 11053
Gene Strand (Orientation) : ?
Protein Name : envelope protein
Protein pI : 7.42
Protein Weight : 50024.4
Protein Length : 559
Protein Note : Flavivirus glycoprotein, central and dimerisation domains; pfam00869

Protein Sequence : Show Sequence

>ABQ63116.1 envelope protein, partial [Dengue virus 1]
MRCVGIGSRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEVTNPAVLRKLCIEAKISNTTT
DSRCPTQGEATLVEEQDANFVCRRTFVDRGWGNGCGLFGKGSLITCAKFKCVTKLEGKIVQYENLKYSVI
VTVHTGDQHQVGNESTEHGTTATITPQAPTTEIQLTDYGALTLDCSPRTGLDFNEMVLLTMKEKSWLVHK
QWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVVVLGSQEGAMHTALTGATEIQTSGTTTIFA
GHLKCRLKMDKLTLKGMSYVMCTGSFKLEKEVAETQHGTVLVQIKYEGTDAPCKIPFSTQDEKGVTQNGR
LITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGDTAW
DFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTCIAVGLVTLYLG
VMVQA

Molecule Role : Protective antigen
Related Vaccine(s): Dengue virus DNA vaccine D1ME encoding prM and E , Dengue Virus DNA Vaccine D1ME-VRP , Dengvaxia , rMV-TDV , TAK-003 , V180 - Aluminum Hydroxide Alhydrogel™ Adjuvant , V180 - ISCOMATRIX™ adjuvant , V180 - unadjuvanted

3. E from Dengue virus 3

Gene Name : E from Dengue virus 3
Sequence Strain (Species/Organism) : Dengue virus 3
NCBI Protein GI : 166092240
Other Database IDs : CDD:279241
CDD:280922
CDD:213897
Taxonomy ID : 11069
Gene Strand (Orientation) : ?
Protein Name : envelope
Protein pI : 7.27
Protein Weight : 50375.82
Protein Length : 549
Protein Note : genotype: I

Protein Sequence : Show Sequence

>ABY82135.1 envelope, partial [Dengue virus 3]
MRCVGVGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDIELQKTEATQLATLRKLCIEGKITNVTT
DSRCPTQGEAILPEEQDQNYVCKHTYVDRGWGNGCGLFGKGSLVTCAKFQCLESIEGKAVQHENLKYTVI
ITVHTGDQHQVGNETQGVTAEITPQASTVEAILPEYGTLGLECSPRTGLDFNEMILLTMKNKAWMVHRQW
FFDLPLPWTSGATTETPTWNKKELLVTFKNAHAKKQEVVVLGSQEGAMHTALTGATEIQTSGGTSIFAGH
LKCRLKMDKLELKGMSYAMCLNAFVLKKEVSETQHGTILIKVEYKGEDAPCKIPFSTEDGQGKAHNGRLI
TANPIVTKKEEPVNIEAEPPFGESNIVIGIGDKALKINWYKKGSSIGKMFEATARGARRMAILGDTAWDF
GSVGGVLNSLGKMVHQIFGSAYTALFSGVSWIMKIGIGVLLTWIGLNSKNTSMSFSCIVIGIITLYLGAV
VQA

Molecule Role : Protective antigen
Related Vaccine(s): Dengvaxia , rMV-TDV , TAK-003 , V180 - Aluminum Hydroxide Alhydrogel™ Adjuvant , V180 - ISCOMATRIX™ adjuvant , V180 - unadjuvanted

4. E from Dengue virus 4

Gene Name : E from Dengue virus 4
Sequence Strain (Species/Organism) : Dengue virus 4
NCBI Protein GI : 369726339
Other Database IDs : CDD:279241
CDD:213392
CDD:213897
Taxonomy ID : 11070
Gene Strand (Orientation) : ?
Protein Name : envelope protein
Protein pI : 7.29
Protein Weight : 49911.732
Protein Length : 559
Protein Note : type: Dengue virus; genotype: IIa

Protein Sequence : Show Sequence

>AEX20298.1 envelope protein, partial [Dengue virus 4]
MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAKEVALLRTYCIEASISNITT
ATRCPTQGEPYLKEEQDQQYICRRDVVDRGWGNGCGLFGKGGVVTCAKFLCSGKITGNLVQIENLEYTVV
VTVHNGDTHAVGNDTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHK
QWFLDLPLPWTAGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMFA
GHLKCKVRMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTVVKVKYEGAGAPCKIPIEIRDVNKEKVVGR
IISSTPFAENTNSVINIELEPPFGDSYIVIGVGDSALTLHWFRKGSSIGKMFESTYRGAKRMAILGETAW
DFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVLWIGTNSRNTSMAMTCIAVGGITLFLG
FTVQA

Molecule Role : Protective antigen
Related Vaccine(s): CAdVax-Den12/Den34 , Dengue Virus DNA Vaccine expressing prM/E proteins , Dengvaxia , rMV-TDV , TAK-003 , TV003/TV005 , V180 - Aluminum Hydroxide Alhydrogel™ Adjuvant , V180 - ISCOMATRIX™ adjuvant , V180 - unadjuvanted

5. E protein from Dengue Virus 2

Gene Name : E protein from Dengue Virus 2
VO ID : VO_0011311
NCBI Protein GI : 202078796
3D structure: PDB ID : 1OAN
Other Database IDs : CDD:279241
CDD:213392
CDD:213897
Taxonomy ID : 11060
Gene Strand (Orientation) : ?
Protein Name : envelope protein
Protein pI : 7.67
Protein Weight : 50568.28
Protein Length : 559
Protein Note : Flavivirus glycoprotein, central and dimerisation domains; pfam00869

Protein Sequence : Show Sequence

>ACH96447.1 envelope protein, partial [Dengue virus 2]
MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKHPATLRKYCIEAKLTNTTT
ASRCPTQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGLFGKGGIVTCAMFTCKKNMEGKIVQPENLEYTIV
ITPHSGEENAVGNDTGKHGKEIKVTPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHR
QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVVVLGSQEGAMHTALTGATEIQMSSGNLLFT
GHLKCRLRMDKLQLKGMSYSMCTGKFKVVKEIAETQHGTIVVRVQYEGDGSPCKIPFEIMDLEKRHVLGR
LITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLSWFKKGSSIGQMFETTMRGAKRMAILGDTAW
DFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVVITWIGMNSRSTSLSVSLVLVGVVTLYLG
VMVQA

Molecule Role : Protective antigen
Molecule Role Annotation : A recombinant baculovirus encoding a dengue (DEN)-2 virus envelope glycoprotein truncated of 102 amino acids (aa) at its C-terminus (D2EA102) was constructed. Both intracellular and extracellular D2EA102 induced neutralizing antibodies in mice and were thus immunogenic. Sixty eight percent (P < 0.001) of mice vaccinated with 5 gg of extracellular D2EA102 protein were protected against lethal challenge (Delenda et al., 1994).
Related Vaccine(s): CAdVax-Den12/Den34 , Dengue Subunit E Protein Vaccine , Dengue virus DNA vaccine 1040D2MEL encoding dengue-2 prM-E-LAMP chimeric protein , Dengue virus DNA vaccine p1012D2ME encoding prM and E from DEN 2 New Guinea C strain , Dengue virus DNA vaccine pE1D2 encoding E from Dengue Virus 2 strain New Guinea C , Dengue virus DNA vaccine sA encoding prM and E from Dengue Virus 4 , Dengue virus DNA vaccine sABC encoding prM and E , Dengue virus DNA vaccine sC encoding prM and E , Dengvaxia , rMV-TDV , TAK-003 , V180 - Aluminum Hydroxide Alhydrogel™ Adjuvant , V180 - ISCOMATRIX™ adjuvant , V180 - unadjuvanted

6. M protein

Gene Name : M protein
VO ID : VO_0011316
NCBI Protein GI : 73671170
Other Database IDs : CDD:279358
Taxonomy ID : 11070
Gene Strand (Orientation) : ?
Protein Name : membrane (M) protein
Protein pI : 7.7
Protein Weight : 8254.03
Protein Length : 129
Protein Note : Flavivirus envelope glycoprotein M; pfam01004

Protein Sequence : Show Sequence

>NP_740316.1 membrane (M) protein [Dengue virus 4]
SVALTPHSGMGLETRAETWMSSEGAWKHAQRVESWILRNPGFALLAGFMAYMIGQTGIQRTVFFVLMMLV
APSYG

Molecule Role : Protective antigen
Molecule Role Annotation : A recombinant vaccinia virus that expressed the M protein of Dengue 4 virus was constructed. Mice immunized with the recombinant virus were protected against subsequent dengue 4 encephalitis challenge (Bray and Lai, 1991).
Related Vaccine(s): Dengue Vaccine using Vaccinia Virus expressing M Protein

7. NS1

Gene Name : NS1
VO ID : VO_0011312
NCBI Protein GI : 288848
Other Database IDs : CDD:213897
CDD:279316
InterPro: IPR001157
UniProtKB/TrEMBL: Q06371
Taxonomy ID : 11060
Gene Strand (Orientation) : ?
Protein pI : 7.2
Protein Weight : 41028.15
Protein Length : 429
Protein Note : flavivirus envelope glycoprotein E, stem/anchor domain; TIGR04240

Protein Sequence : Show Sequence

>CAA78918.1 NS1, partial [Dengue virus 2]
MNSRSTSLSVSQVLVGIVTLYLGVMVQADSGCVVSWKNKELKCGSGIFVTDNVHTRTEQYKFQPESPSKL
ASAIQKAHEEGICGIRSVTRLENLMWKQITSELNHILSENEVKLTIMTGDIKGIMQVGKRSLRPQPTELR
YSWKTWGKAKMLSTELHNQTFLIDGPETAECPNTNRAWNSLEVEDYGFGVFTTNIWLRLREKQDAFCDSK
LMSAAIKDNRAVHADMGYWIESALNDTWKIEKASFIEVKSCHWPKSHTLWSNGVLESEMVIPKNFAGPKS
QHNNRPGYHTQTAGPWHLGKLEMDFDFCEGTTVVVTEDCGNRGPSLRTTTASGKLITEWCCRSCTLPPLR
YRGEDGCWYGMEIRPLKEKEENLVSSLVTA

Molecule Role : Protective antigen
Molecule Role Annotation : The protective efficacy and immune responses of mice intramuscularly injected with plasmid encoding DEN-2 non-structural protein 1 (NS1) was evaluated. Intravenously challenged by lethal DEN-2, mice vaccinated with NS1-DNA exhibited a delay onset of paralysis, a marked decrease of morbidity, and a significant enhancement of survival (Wu et al., 2003).
Related Vaccine(s): Dengue DNA Vaccine encoding NS1 Protein , Dengue Virus DNA Vaccine encoding NS1 , Dengue virus DNA vaccine pcTPANS1 encoding NS1 fused to the tissue plasminogen activator signal sequence

8. POLY

Gene Name : POLY
Sequence Strain (Species/Organism) : Yellow fever virus
NCBI Gene ID : 1502173
NCBI Protein GI : 9627245
Locus Tag : YFVgp1
Genbank Accession : X03700
Protein Accession : NP_041726
Taxonomy ID : 11089
Gene Starting Position : 0
Gene Ending Position : 10861
Gene Strand (Orientation) : +
Protein Name : mRNA
Protein pI : 8.51
Protein Weight : 351142.06
Protein Length : 3411

DNA Sequence : Show Sequence

>NC_002031.1:1-10861 Yellow fever virus, complete genome
AGTAAATCCTGTGTGCTAATTGAGGTGCATTGGTCTGCAAATCGAGTTGCTAGGCAATAAACACATTTGG
ATTAATTTTAATCGTTCGTTGAGCGATTAGCAGAGAACTGACCAGAACATGTCTGGTCGTAAAGCTCAGG
GAAAAACCCTGGGCGTCAATATGGTACGACGAGGAGTTCGCTCCTTGTCAAACAAAATAAAACAAAAAAC
AAAACAAATTGGAAACAGACCTGGACCTTCAAGAGGTGTTCAAGGATTTATCTTTTTCTTTTTGTTCAAC
ATTTTGACTGGAAAAAAGATCACAGCCCACCTAAAGAGGTTGTGGAAAATGCTGGACCCAAGACAAGGCT
TGGCTGTTCTAAGGAAAGTCAAGAGAGTGGTGGCCAGTTTGATGAGAGGATTGTCCTCAAGGAAACGCCG
TTCCCATGATGTTCTGACTGTGCAATTCCTAATTTTGGGAATGCTGTTGATGACGGGTGGAGTGACCTTG
GTGCGGAAAAACAGATGGTTGCTCCTAAATGTGACATCTGAGGACCTCGGGAAAACATTCTCTGTGGGCA
CAGGCAACTGCACAACAAACATTTTGGAAGCCAAGTACTGGTGCCCAGACTCAATGGAATACAACTGTCC
CAATCTCAGTCCAAGAGAGGAGCCAGATGACATTGATTGCTGGTGCTATGGGGTGGAAAACGTTAGAGTC
GCATATGGTAAGTGTGACTCAGCAGGCAGGTCTAGGAGGTCAAGAAGGGCCATTGACTTGCCTACGCATG
AAAACCATGGTTTGAAGACCCGGCAAGAAAAATGGATGACTGGAAGAATGGGTGAAAGGCAACTCCAAAA
GATTGAGAGATGGTTCGTGAGGAACCCCTTTTTTGCAGTGACGGCTCTGACCATTGCCTACCTTGTGGGA
AGCAACATGACGCAACGAGTCGTGATTGCCCTACTGGTCTTGGCTGTTGGTCCGGCCTACTCAGCTCACT
GCATTGGAATTACTGACAGGGATTTCATTGAGGGGGTGCATGGAGGAACTTGGGTTTCAGCTACCCTGGA
GCAAGACAAGTGTGTCACTGTTATGGCCCCTGACAAGCCTTCATTGGACATCTCACTAGAGACAGTAGCC
ATTGATAGACCTGCTGAGGTGAGGAAAGTGTGTTACAATGCAGTTCTCACTCATGTGAAGATTAATGACA
AGTGCCCCAGCACTGGAGAGGCCCACCTAGCTGAAGAGAACGAAGGGGACAATGCGTGCAAGCGCACTTA
TTCTGATAGAGGCTGGGGCAATGGCTGTGGCCTATTTGGGAAAGGGAGCATTGTGGCATGCGCCAAATTC
ACTTGTGCCAAATCCATGAGTTTGTTTGAGGTTGATCAGACCAAAATTCAGTATGTCATCAGAGCACAAT
TGCATGTAGGGGCCAAGCAGGAAAATTGGAATACCGACATTAAGACTCTCAAGTTTGATGCCCTGTCAGG
CTCCCAGGAAGTCGAGTTCATTGGGTATGGAAAAGCTACACTGGAATGCCAGGTGCAAACTGCGGTGGAC
TTTGGTAACAGTTACATCGCTGAGATGGAAACAGAGAGCTGGATAGTGGACAGACAGTGGGCCCAGGACT
TGACCCTGCCATGGCAGAGTGGAAGTGGCGGGGTGTGGAGAGAGATGCATCATCTTGTCGAATTTGAACC
TCCGCATGCCGCCACTATCAGAGTACTGGCCCTGGGAAACCAGGAAGGCTCCTTGAAAACAGCTCTTACT
GGCGCAATGAGGGTTACAAAGGACACAAATGACAACAACCTTTACAAACTACATGGTGGACATGTTTCTT
GCAGAGTGAAATTGTCAGCTTTGACACTCAAGGGGACATCCTACAAAATATGCACTGACAAAATGTTTTT
TGTCAAGAACCCAACTGACACTGGCCATGGCACTGTTGTGATGCAGGTGAAAGTGTCAAAAGGAGCCCCC
TGCAGGATTCCAGTGATAGTAGCTGATGATCTTACAGCGGCAATCAATAAAGGCATTTTGGTTACAGTTA
ACCCCATCGCCTCAACCAATGATGATGAAGTGCTGATTGAGGTGAACCCACCTTTTGGAGACAGCTACAT
TATCGTTGGGAGAGGAGATTCACGTCTCACTTACCAGTGGCACAAAGAGGGAAGCTCAATAGGAAAGTTG
TTCACTCAGACCATGAAAGGCGTGGAACGCCTGGCCGTCATGGGAGACACCGCCTGGGATTTCAGCTCCG
CTGGAGGGTTCTTCACTTCGGTTGGGAAAGGAATTCATACGGTGTTTGGCTCTGCCTTTCAGGGGCTATT
TGGCGGCTTGAACTGGATAACAAAGGTCATCATGGGGGCGGTACTTATATGGGTTGGCATCAACACAAGA
AACATGACAATGTCCATGAGCATGATCTTGGTAGGAGTGATCATGATGTTTTTGTCTCTAGGAGTTGGGG
CGGATCAAGGATGCGCCATCAACTTTGGCAAGAGAGAGCTCAAGTGCGGAGATGGTATCTTCATATTTAG
AGACTCTGATGACTGGCTGAACAAGTACTCATACTATCCAGAAGATCCTGTGAAGCTTGCATCAATAGTG
AAAGCCTCTTTTGAAGAAGGGAAGTGTGGCCTAAATTCAGTTGACTCCCTTGAGCATGAGATGTGGAGAA
GCAGGGCAGATGAGATCAATGCCATTTTTGAGGAAAACGAGGTGGACATTTCTGTTGTCGTGCAGGATCC
AAAGAATGTTTACCAGAGAGGAACTCATCCATTTTCCAGAATTCGGGATGGTCTGCAGTATGGTTGGAAG
ACTTGGGGTAAGAACCTTGTGTTCTCCCCAGGGAGGAAGAATGGAAGCTTCATCATAGATGGAAAGTCCA
GGAAAGAATGCCCGTTTTCAAACCGGGTCTGGAATTCTTTCCAGATAGAGGAGTTTGGGACGGGAGTGTT
CACCACACGCGTGTACATGGACGCAGTCTTTGAATACACCATAGACTGCGATGGATCTATCTTGGGTGCA
GCGGTGAACGGAAAAAAGAGTGCCCATGGCTCTCCAACATTTTGGATGGGAAGTCATGAAGTAAATGGGA
CATGGATGATCCACACCTTGGAGGCATTAGATTACAAGGAGTGTGAGTGGCCACTGACACATACGATTGG
AACATCAGTTGAAGAGAGTGAAATGTTCATGCCGAGATCAATCGGAGGCCCAGTTAGCTCTCACAATCAT
ATCCCTGGATACAAGGTTCAGACGAACGGACCTTGGATGCAGGTACCACTAGAAGTGAAGAGAGAAGCTT
GCCCAGGGACTAGCGTGATCATTGATGGCAACTGTGATGGACGGGGAAAATCAACCAGATCCACCACGGA
TAGCGGGAAAGTTATTCCTGAATGGTGTTGCCGCTCCTGCACAATGCCGCCTGTGAGCTTCCATGGTAGT
GATGGGTGTTGGTATCCCATGGAAATTAGGCCAAGGAAAACGCATGAAAGCCATCTGGTGCGCTCCTGGG
TTACAGCTGGAGAAATACATGCTGTCCCTTTTGGTTTGGTGAGCATGATGATAGCAATGGAAGTGGTCCT
AAGGAAAAGACAGGGACCAAAGCAAATGTTGGTTGGAGGAGTAGTGCTCTTGGGAGCAATGCTGGTCGGG
CAAGTAACTCTCCTTGATTTGCTGAAACTCACAGTGGCTGTGGGATTGCATTTCCATGAGATGAACAATG
GAGGAGACGCCATGTATATGGCGTTGATTGCTGCCTTTTCAATCAGACCAGGGCTGCTCATCGGCTTTGG
GCTCAGGACCCTATGGAGCCCTCGGGAACGCCTTGTGCTGACCCTAGGAGCAGCCATGGTGGAGATTGCC
TTGGGTGGCGTGATGGGCGGCCTGTGGAAGTATCTAAATGCAGTTTCTCTCTGCATCCTGACAATAAATG
CTGTTGCTTCTAGGAAAGCATCAAATACCATCTTGCCCCTCATGGCTCTGTTGACACCTGTCACTATGGC
TGAGGTGAGACTTGCCGCAATGTTCTTTTGTGCCGTGGTTATCATAGGGGTCCTTCACCAGAATTTCAAG
GACACCTCCATGCAGAAGACTATACCTCTGGTGGCCCTCACACTCACATCTTACCTGGGCTTGACACAAC
CTTTTTTGGGCCTGTGTGCATTTCTGGCAACCCGCATATTTGGGCGAAGGAGTATCCCAGTGAATGAGGC
ACTCGCAGCAGCTGGTCTAGTGGGAGTGCTGGCAGGACTGGCTTTTCAGGAGATGGAGAACTTCCTTGGT
CCGATTGCAGTTGGAGGACTCCTGATGATGCTGGTTAGCGTGGCTGGGAGGGTGGATGGGCTAGAGCTCA
AGAAGCTTGGTGAAGTTTCATGGGAAGAGGAGGCGGAGATCAGCGGGAGTTCCGCCCGCTATGATGTGGC
ACTCAGTGAACAAGGGGAGTTCAAGCTGCTTTCTGAAGAGAAAGTGCCATGGGACCAGGTTGTGATGACC
TCGCTGGCCTTGGTTGGGGCTGCCCTCCATCCATTTGCTCTTCTGCTGGTCCTTGCTGGGTGGCTGTTTC
ATGTCAGGGGAGCTAGGAGAAGTGGGGATGTCTTGTGGGATATTCCCACTCCTAAGATCATCGAGGAATG
TGAACATCTGGAGGATGGGATTTATGGCATATTCCAGTCAACCTTCTTGGGGGCCTCCCAGCGAGGAGTG
GGAGTGGCACAGGGAGGGGTGTTCCACACAATGTGGCATGTCACAAGAGGAGCTTTCCTTGTCAGGAATG
GCAAGAAGTTGATTCCATCTTGGGCTTCAGTAAAGGAAGACCTTGTCGCCTATGGTGGCTCATGGAAGTT
GGAAGGCAGATGGGATGGAGAGGAAGAGGTCCAGTTGATCGCGGCTGTTCCAGGAAAGAACGTGGTCAAC
GTCCAGACAAAACCGAGCTTGTTCAAAGTGAGGAATGGGGGAGAAATCGGGGCTGTCGCTCTTGACTATC
CGAGTGGCACTTCAGGATCTCCTATTGTTAACAGGAACGGAGAGGTGATTGGGCTGTACGGCAATGGCAT
CCTTGTCGGTGACAACTCCTTCGTGTCCGCCATATCCCAGACTGAGGTGAAGGAAGAAGGAAAGGAGGAG
CTCCAAGAGATCCCGACAATGCTAAAGAAAGGAATGACAACTGTCCTTGATTTTCATCCTGGAGCTGGGA
AGACAAGACGTTTCCTCCCACAGATCTTGGCCGAGTGCGCACGGAGACGCTTGCGCACTCTTGTGTTGGC
CCCCACCAGGGTTGTTCTTTCTGAAATGAAGGAGGCTTTTCACGGCCTGGACGTGAAATTCCACACACAG
GCTTTTTCCGCTCACGGCAGCGGGAGAGAAGTCATTGATGCCATGTGCCATGCCACCCTAACTTACAGGA
TGTTGGAACCAACTAGGGTTGTTAACTGGGAAGTGATCATTATGGATGAAGCCCATTTTTTGGATCCAGC
TAGCATAGCCGCTAGAGGTTGGGCAGCGCACAGAGCTAGGGCAAATGAAAGTGCAACAATCTTGATGACA
GCCACACCGCCTGGGACTAGTGATGAATTTCCACATTCAAATGGTGAAATAGAAGATGTTCAAACGGACA
TACCCAGTGAGCCCTGGAACACAGGGCATGACTGGATCCTAGCTGACAAAAGGCCCACGGCATGGTTCCT
TCCATCCATCAGAGCTGCAAATGTCATGGCTGCCTCTTTGCGTAAGGCTGGAAAGAGTGTGGTGGTCCTG
AACAGGAAAACCTTTGAGAGAGAATACCCCACGATAAAGCAGAAGAAACCTGACTTTATATTGGCCACTG
ACATAGCTGAAATGGGAGCCAACCTTTGCGTGGAGCGAGTGCTGGATTGCAGGACGGCTTTTAAGCCTGT
GCTTGTGGATGAAGGGAGGAAGGTGGCAATAAAAGGGCCACTTCGTATCTCCGCATCCTCTGCTGCTCAA
AGGAGGGGGCGCATTGGGAGAAATCCCAACAGAGATGGAGACTCATACTACTATTCTGAGCCTACAAGTG
AAAATAATGCCCACCACGTCTGCTGGTTGGAGGCCTCAATGCTCTTGGACAACATGGAGGTGAGGGGTGG
AATGGTCGCCCCACTCTATGGCGTTGAAGGAACTAAAACACCAGTTTCCCCTGGTGAAATGAGACTGAGG
GATGACCAGAGGAAAGTCTTCAGAGAACTAGTGAGGAATTGTGACCTGCCCGTTTGGCTTTCGTGGCAAG
TGGCCAAGGCTGGTTTGAAGACGAATGATCGTAAGTGGTGTTTTGAAGGCCCTGAGGAACATGAGATCTT
GAATGACAGCGGTGAAACAGTGAAGTGCAGGGCTCCTGGAGGAGCAAAGAAGCCTCTGCGCCCAAGGTGG
TGTGATGAAAGGGTGTCATCTGACCAGAGTGCGCTGTCTGAATTTATTAAGTTTGCTGAAGGTAGGAGGG
GAGCTGCTGAAGTGCTAGTTGTGCTGAGTGAACTCCCTGATTTCCTGGCTAAAAAAGGTGGAGAGGCAAT
GGATACCATCAGTGTGTTCCTCCACTCTGAGGAAGGCTCTAGGGCTTACCGCAATGCACTATCAATGATG
CCTGAGGCAATGACAATAGTCATGCTGTTTATACTGGCTGGACTACTGACATCGGGAATGGTCATCTTTT
TCATGTCTCCCAAAGGCATCAGTAGAATGTCTATGGCGATGGGCACAATGGCCGGCTGTGGATATCTCAT
GTTCCTTGGAGGCGTCAAACCCACTCACATCTCCTATGTCATGCTCATATTCTTTGTCCTGATGGTGGTT
GTGATCCCCGAGCCAGGGCAACAAAGGTCCATCCAAGACAACCAAGTGGCATACCTCATTATTGGCATCC
TGACGCTGGTTTCAGCGGTGGCAGCCAACGAGCTAGGCATGCTGGAGAAAACCAAAGAGGACCTCTTTGG
GAAGAAGAACTTAATTCCATCTAGTGCTTCACCCTGGAGTTGGCCGGATCTTGACCTGAAGCCAGGAGCT
GCCTGGACAGTGTACGTTGGCATTGTTACAATGCTCTCTCCAATGTTGCACCACTGGATCAAAGTCGAAT
ATGGCAACCTGTCTCTGTCTGGAATAGCCCAGTCAGCCTCAGTCCTTTCTTTCATGGACAAGGGGATACC
ATTCATGAAGATGAATATCTCGGTCATAATGCTGCTGGTCAGTGGCTGGAATTCAATAACAGTGATGCCT
CTGCTCTGTGGCATAGGGTGCGCCATGCTCCACTGGTCTCTCATTTTACCTGGAATCAAAGCGCAGCAGT
CAAAGCTTGCACAGAGAAGGGTGTTCCATGGCGTTGCCGAGAACCCTGTGGTTGATGGGAATCCAACAGT
TGACATTGAGGAAGCTCCTGAAATGCCTGCCCTTTATGAGAAGAAACTGGCTCTATATCTCCTTCTTGCT
CTCAGCCTAGCTTCTGTTGCCATGTGCAGAACGCCCTTTTCATTGGCTGAAGGCATTGTCCTAGCATCAG
CTGCCTTAGGGCCGCTCATAGAGGGAAACACCAGCCTTCTTTGGAATGGACCCATGGCTGTCTCCATGAC
AGGAGTCATGAGGGGGAATCACTATGCTTTTGTGGGAGTCATGTACAATCTATGGAAGATGAAAACTGGA
CGCCGGGGGAGCGCGAATGGAAAAACTTTGGGTGAAGTCTGGAAGAGGGAACTGAATCTGTTGGACAAGC
GACAGTTTGAGTTGTATAAAAGGACCGACATTGTGGAGGTGGATCGTGATACGGCACGCAGGCATTTGGC
CGAAGGGAAGGTGGACACCGGGGTGGCGGTCTCCAGGGGGACCGCAAAGTTAAGGTGGTTCCATGAGCGT
GGCTATGTCAAGCTGGAAGGTAGGGTGATTGACCTGGGGTGTGGCCGCGGAGGCTGGTGTTACTACGCTG
CTGCGCAAAAGGAAGTGAGTGGGGTCAAAGGATTTACTCTTGGAAGAGACGGCCATGAGAAACCCATGAA
TGTGCAAAGTCTGGGATGGAACATCATCACCTTCAAGGACAAAACTGATATCCACCGCCTAGAACCAGTG
AAATGTGACACCCTTTTGTGTGACATTGGAGAGTCATCATCGTCATCGGTCACAGAGGGGGAAAGGACCG
TGAGAGTTCTTGATACTGTAGAAAAATGGCTGGCTTGTGGGGTTGACAACTTCTGTGTGAAGGTGTTAGC
TCCATACATGCCAGATGTTCTCGAGAAACTGGAATTGCTCCAAAGGAGGTTTGGCGGAACAGTGATCAGG
AACCCTCTCTCCAGGAATTCCACTCATGAAATGTACTACGTGTCTGGAGCCCGCAGCAATGTCACATTTA
CTGTGAACCAAACATCCCGCCTCCTGATGAGGAGAATGAGGCGTCCAACTGGAAAAGTGACCCTGGAGGC
TGACGTCATCCTCCCAATTGGGACACGCAGTGTTGAGACAGACAAGGGACCCCTGGACAAAGAGGCCATA
GAAGAAAGGGTTGAGAGGATAAAATCTGAGTACATGACCTCTTGGTTTTATGACAATGACAACCCCTACA
GGACCTGGCACTACTGTGGCTCCTATGTCACAAAAACCTCAGGAAGTGCGGCGAGCATGGTAAATGGTGT
TATTAAAATTCTGACATATCCATGGGACAGGATAGAGGAGGTCACAAGAATGGCAATGACTGACACAACC
CCTTTTGGACAGCAAAGAGTGTTTAAAGAAAAAGTTGACACCAGAGCAAAGGATCCACCAGCGGGAACTA
GGAAGATCATGAAAGTTGTCAACAGGTGGCTGTTCCGCCACCTGGCCAGAGAAAAGAACCCCAGACTGTG
CACAAAGGAAGAATTTATTGCAAAAGTCCGAAGTCATGCAGCCATTGGAGCTTACCTGGAAGAACAAGAA
CAGTGGAAGACTGCCAATGAGGCTGTCCAAGACCCAAAGTTCTGGGAACTGGTGGATGAAGAAAGGAAGC
TGCACCAACAAGGCAGGTGTCGGACTTGTGTGTACAACATGATGGGGAAAAGAGAGAAGAAGCTGTCAGA
GTTTGGGAAAGCAAAGGGAAGCCGTGCCATATGGTATATGTGGCTGGGAGCGCGGTATCTTGAGTTTGAG
GCCCTGGGATTCCTGAATGAGGACCATTGGGCTTCCAGGGAAAACTCAGGAGGAGGAGTGGAAGGCATTG
GCTTACAATACCTAGGATATGTGATCAGAGACCTGGCTGCAATGGATGGTGGTGGATTCTACGCGGATGA
CACCGCTGGATGGGACACGCGCATCACAGAGGCAGACCTTGATGATGAACAGGAGATCTTGAACTACATG
AGCCCACATCACAAAAAACTGGCACAAGCAGTGATGGAAATGACATACAAGAACAAAGTGGTGAAAGTGT
TGAGACCAGCCCCAGGAGGGAAAGCCTACATGGATGTCATAAGTCGACGAGACCAGAGAGGATCCGGGCA
GGTAGTGACTTATGCTCTGAACACCATCACCAACTTGAAAGTCCAATTGATCAGAATGGCAGAAGCAGAG
ATGGTGATACATCACCAACATGTTCAAGATTGTGATGAATCAGTTCTGACCAGGCTGGAGGCATGGCTCA
CTGAGCACGGATGTGACAGACTGAAGAGGATGGCGGTGAGTGGAGACGACTGTGTGGTCCGGCCCATCGA
TGACAGGTTCGGCCTGGCCCTGTCCCATCTCAACGCCATGTCCAAGGTTAGAAAGGACATATCTGAATGG
CAGCCATCAAAAGGGTGGAATGATTGGGAGAATGTGCCCTTCTGTTCCCACCACTTCCATGAACTACAGC
TGAAGGATGGCAGGAGGATTGTGGTGCCTTGCCGAGAACAGGACGAGCTCATTGGGAGAGGAAGGGTGTC
TCCAGGAAACGGCTGGATGATCAAGGAAACAGCTTGCCTCAGCAAAGCCTATGCCAACATGTGGTCACTG
ATGTATTTTCACAAAAGGGACATGAGGCTACTGTCATTGGCTGTTTCCTCAGCTGTTCCCACCTCATGGG
TTCCACAAGGACGCACAACATGGTCGATTCATGGGAAAGGGGAGTGGATGACCACGGAAGACATGCTTGA
GGTGTGGAACAGAGTATGGATAACCAACAACCCACACATGCAGGACAAGACAATGGTGAAAAAATGGAGA
GATGTCCCTTATCTAACCAAGAGACAAGACAAGCTGTGCGGATCACTGATTGGAATGACCAATAGGGCCA
CCTGGGCCTCCCACATCCATTTAGTCATCCATCGTATCCGAACGCTGATTGGACAGGAGAAATACACTGA
CTACCTAACAGTCATGGACAGGTATTCTGTGGATGCTGACCTGCAACTGGGTGAGCTTATCTGAAACACC
ATCTAACAGGAATAACCGGGATACAAACCACGGGTGGAGAACCGGACTCCCCACAACCTGAAACCGGGAT
ATAAACCACGGCTGGAGAACCGGGCTCCGCACTTAAAATGAAACAGAAACCGGGATAAAAACTACGGATG
GAGAACCGGACTCCACACATTGAGACAGAAGAAGTTGTCAGCCCAGAACCCCACACGAGTTTTGCCACTG
CTAAGCTGTGAGGCAGTGCAGGCTGGGACAGCCGACCTCCAGGTTGCGAAAAACCTGGTTTCTGGGACCT
CCCACCCCAGAGTAAAAAGAACGGAGCCTCCGCTACCACCCTCCCACGTGGTGGTAGAAAGACGGGGTCT
AGAGGTTAGAGGAGACCCTCCAGGGAACAAATAGTGGGACCATATTGACGCCAGGGAAAGACCGGAGTGG
TTCTCTGCTTTTCCTCCAGAGGTCTGTGAGCACAGTTTGCTCAAGAATAAGCAGACCTTTGGATGACAAA
CACAAAACCAC

Protein Sequence : Show Sequence

>NP_041726.1 polyprotein precursor [Yellow fever virus]
MSGRKAQGKTLGVNMVRRGVRSLSNKIKQKTKQIGNRPGPSRGVQGFIFFFLFNILTGKKITAHLKRLWK
MLDPRQGLAVLRKVKRVVASLMRGLSSRKRRSHDVLTVQFLILGMLLMTGGVTLVRKNRWLLLNVTSEDL
GKTFSVGTGNCTTNILEAKYWCPDSMEYNCPNLSPREEPDDIDCWCYGVENVRVAYGKCDSAGRSRRSRR
AIDLPTHENHGLKTRQEKWMTGRMGERQLQKIERWFVRNPFFAVTALTIAYLVGSNMTQRVVIALLVLAV
GPAYSAHCIGITDRDFIEGVHGGTWVSATLEQDKCVTVMAPDKPSLDISLETVAIDRPAEVRKVCYNAVL
THVKINDKCPSTGEAHLAEENEGDNACKRTYSDRGWGNGCGLFGKGSIVACAKFTCAKSMSLFEVDQTKI
QYVIRAQLHVGAKQENWNTDIKTLKFDALSGSQEVEFIGYGKATLECQVQTAVDFGNSYIAEMETESWIV
DRQWAQDLTLPWQSGSGGVWREMHHLVEFEPPHAATIRVLALGNQEGSLKTALTGAMRVTKDTNDNNLYK
LHGGHVSCRVKLSALTLKGTSYKICTDKMFFVKNPTDTGHGTVVMQVKVSKGAPCRIPVIVADDLTAAIN
KGILVTVNPIASTNDDEVLIEVNPPFGDSYIIVGRGDSRLTYQWHKEGSSIGKLFTQTMKGVERLAVMGD
TAWDFSSAGGFFTSVGKGIHTVFGSAFQGLFGGLNWITKVIMGAVLIWVGINTRNMTMSMSMILVGVIMM
FLSLGVGADQGCAINFGKRELKCGDGIFIFRDSDDWLNKYSYYPEDPVKLASIVKASFEEGKCGLNSVDS
LEHEMWRSRADEINAIFEENEVDISVVVQDPKNVYQRGTHPFSRIRDGLQYGWKTWGKNLVFSPGRKNGS
FIIDGKSRKECPFSNRVWNSFQIEEFGTGVFTTRVYMDAVFEYTIDCDGSILGAAVNGKKSAHGSPTFWM
GSHEVNGTWMIHTLEALDYKECEWPLTHTIGTSVEESEMFMPRSIGGPVSSHNHIPGYKVQTNGPWMQVP
LEVKREACPGTSVIIDGNCDGRGKSTRSTTDSGKVIPEWCCRSCTMPPVSFHGSDGCWYPMEIRPRKTHE
SHLVRSWVTAGEIHAVPFGLVSMMIAMEVVLRKRQGPKQMLVGGVVLLGAMLVGQVTLLDLLKLTVAVGL
HFHEMNNGGDAMYMALIAAFSIRPGLLIGFGLRTLWSPRERLVLTLGAAMVEIALGGVMGGLWKYLNAVS
LCILTINAVASRKASNTILPLMALLTPVTMAEVRLAAMFFCAVVIIGVLHQNFKDTSMQKTIPLVALTLT
SYLGLTQPFLGLCAFLATRIFGRRSIPVNEALAAAGLVGVLAGLAFQEMENFLGPIAVGGLLMMLVSVAG
RVDGLELKKLGEVSWEEEAEISGSSARYDVALSEQGEFKLLSEEKVPWDQVVMTSLALVGAALHPFALLL
VLAGWLFHVRGARRSGDVLWDIPTPKIIEECEHLEDGIYGIFQSTFLGASQRGVGVAQGGVFHTMWHVTR
GAFLVRNGKKLIPSWASVKEDLVAYGGSWKLEGRWDGEEEVQLIAAVPGKNVVNVQTKPSLFKVRNGGEI
GAVALDYPSGTSGSPIVNRNGEVIGLYGNGILVGDNSFVSAISQTEVKEEGKEELQEIPTMLKKGMTTVL
DFHPGAGKTRRFLPQILAECARRRLRTLVLAPTRVVLSEMKEAFHGLDVKFHTQAFSAHGSGREVIDAMC
HATLTYRMLEPTRVVNWEVIIMDEAHFLDPASIAARGWAAHRARANESATILMTATPPGTSDEFPHSNGE
IEDVQTDIPSEPWNTGHDWILADKRPTAWFLPSIRAANVMAASLRKAGKSVVVLNRKTFEREYPTIKQKK
PDFILATDIAEMGANLCVERVLDCRTAFKPVLVDEGRKVAIKGPLRISASSAAQRRGRIGRNPNRDGDSY
YYSEPTSENNAHHVCWLEASMLLDNMEVRGGMVAPLYGVEGTKTPVSPGEMRLRDDQRKVFRELVRNCDL
PVWLSWQVAKAGLKTNDRKWCFEGPEEHEILNDSGETVKCRAPGGAKKPLRPRWCDERVSSDQSALSEFI
KFAEGRRGAAEVLVVLSELPDFLAKKGGEAMDTISVFLHSEEGSRAYRNALSMMPEAMTIVMLFILAGLL
TSGMVIFFMSPKGISRMSMAMGTMAGCGYLMFLGGVKPTHISYVMLIFFVLMVVVIPEPGQQRSIQDNQV
AYLIIGILTLVSAVAANELGMLEKTKEDLFGKKNLIPSSASPWSWPDLDLKPGAAWTVYVGIVTMLSPML
HHWIKVEYGNLSLSGIAQSASVLSFMDKGIPFMKMNISVIMLLVSGWNSITVMPLLCGIGCAMLHWSLIL
PGIKAQQSKLAQRRVFHGVAENPVVDGNPTVDIEEAPEMPALYEKKLALYLLLALSLASVAMCRTPFSLA
EGIVLASAALGPLIEGNTSLLWNGPMAVSMTGVMRGNHYAFVGVMYNLWKMKTGRRGSANGKTLGEVWKR
ELNLLDKRQFELYKRTDIVEVDRDTARRHLAEGKVDTGVAVSRGTAKLRWFHERGYVKLEGRVIDLGCGR
GGWCYYAAAQKEVSGVKGFTLGRDGHEKPMNVQSLGWNIITFKDKTDIHRLEPVKCDTLLCDIGESSSSS
VTEGERTVRVLDTVEKWLACGVDNFCVKVLAPYMPDVLEKLELLQRRFGGTVIRNPLSRNSTHEMYYVSG
ARSNVTFTVNQTSRLLMRRMRRPTGKVTLEADVILPIGTRSVETDKGPLDKEAIEERVERIKSEYMTSWF
YDNDNPYRTWHYCGSYVTKTSGSAASMVNGVIKILTYPWDRIEEVTRMAMTDTTPFGQQRVFKEKVDTRA
KDPPAGTRKIMKVVNRWLFRHLAREKNPRLCTKEEFIAKVRSHAAIGAYLEEQEQWKTANEAVQDPKFWE
LVDEERKLHQQGRCRTCVYNMMGKREKKLSEFGKAKGSRAIWYMWLGARYLEFEALGFLNEDHWASRENS
GGGVEGIGLQYLGYVIRDLAAMDGGGFYADDTAGWDTRITEADLDDEQEILNYMSPHHKKLAQAVMEMTY
KNKVVKVLRPAPGGKAYMDVISRRDQRGSGQVVTYALNTITNLKVQLIRMAEAEMVIHHQHVQDCDESVL
TRLEAWLTEHGCDRLKRMAVSGDDCVVRPIDDRFGLALSHLNAMSKVRKDISEWQPSKGWNDWENVPFCS
HHFHELQLKDGRRIVVPCREQDELIGRGRVSPGNGWMIKETACLSKAYANMWSLMYFHKRDMRLLSLAVS
SAVPTSWVPQGRTTWSIHGKGEWMTTEDMLEVWNRVWITNNPHMQDKTMVKKWRDVPYLTKRQDKLCGSL
IGMTNRATWASHIHLVIHRIRTLIGQEKYTDYLTVMDRYSVDADLQLGELI

Molecule Role : Protective antigen
Related Vaccine(s): Dengvaxia

9. POLY

Gene Name : POLY
Sequence Strain (Species/Organism) : Dengue virus 2
NCBI Gene ID : 1494449
NCBI Protein GI : 159024209
Locus Tag : DENV_gp1
Genbank Accession : KU725663
Protein Accession : NP_056776
Taxonomy ID : 11060
Gene Starting Position : 96
Gene Ending Position : 10271
Gene Strand (Orientation) : +
Protein Name : polyprotein
Protein pI : 8.66
Protein Weight : 358266.86
Protein Length : 3391
Protein Note : Also known as polyprotein genecontains structural proteins, C-prM/M-E and non-structural proteins, NS1-NS2A/B-NS3-NS4A/B-NS5

Protein Sequence : Show Sequence

>NP_056776.2 polyprotein [Dengue virus type 2]
MNNQRKKAKNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLFMALVAFLRFLTIPPTAGILKRWG
TIKKSKAINVLRGFRKEIGRMLNILNRRRRSAGMIIMLIPTVMAFHLTTRNGEPHMIVSRQEKGKSLLFK
TEDGVNMCTLMAMDLGELCEDTITYKCPLLRQNEPEDIDCWCNSTSTWVTYGTCTTMGEHRREKRSVALV
PHVGMGLETRTETWMSSEGAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMT
MRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTT
ESRCPTQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGLFGKGGIVTCAMFRCKKNMEGKVVQPENLEYTIV
ITPHSGEEHAVGNDTGKHGKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHR
QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVVVLGSQEGAMHTALTGATEIQMSSGNLLFT
GHLKCRLRMDKLQLKGMSYSMCTGKFKVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGR
LITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRGAKRMAILGDTAW
DFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLG
VMVQADSGCVVSWKNKELKCGSGIFITDNVHTWTEQYKFQPESPSKLASAIQKAHEEGICGIRSVTRLEN
LMWKQITPELNHILSENEVKLTIMTGDIKGIMQAGKRSLRPQPTELKYSWKTWGKAKMLSTESHNQTFLI
DGPETAECPNTNRAWNSLEVEDYGFGVFTTNIWLKLKEKQDVFCDSKLMSAAIKDNRAVHADMGYWIESA
LNDTWKIEKASFIEVKNCHWPKSHTLWSNGVLESEMIIPKNLAGPVSQHNYRPGYHTQITGPWHLGKLEM
DFDFCDGTTVVVTEDCGNRGPSLRTTTASGKLITEWCCRSCTLPPLRYRGEDGCWYGMEIRPLKEKEENL
VNSLVTAGHGQVDNFSLGVLGMALFLEEMLRTRVGTKHAILLVAVSFVTLITGNMSFRDLGRVMVMVGAT
MTDDIGMGVTYLALLAAFKVRPTFAAGLLLRKLTSKELMMTTIGIVLLSQSTIPETILELTDALALGMMV
LKMVRNMEKYQLAVTIMAILCVPNAVILQNAWKVSCTILAVVSVSPLLLTSSQQKTDWIPLALTIKGLNP
TAIFLTTLSRTSKKRSWPLNEAIMAVGMVSILASSLLKNDIPMTGPLVAGGLLTVCYVLTGRSADLELER
AADVKWEDQAEISGSSPILSITISEDGSMSIKNEEEEQTLTILIRTGLLVISGLFPVSIPITAAAWYLWE
VKKQRAGVLWDVPSPPPMGKAELEDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRI
EPSWADVKKDLISYGGGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSLDFSPGTS
GSPIIDKKGKVVGLYGNGVVTRSGAYVSAIAQTEKSIEDNPEIEDDIFRKRRLTIMDLHPGAGKTKRYLP
AIVREAIKRGLRTLILAPTRVVAAEMEEALRGLPIRYQTPAIRAEHTGREIVDLMCHATFTMRLLSPVRV
PNYNLIIMDEAHFTDPASIAARGYISTRVEMGEAAGIFMTATPPGSRDPFPQSNAPIIDEEREIPERSWN
SGHEWVTDFKGKTVWFVPSIKAGNDIAACLRKNGKKVIQLSRKTFDSEYVKTRTNDWDFVVTTDISEMGA
NFKAERVIDPRRCMKPVILTDGEERVILAGPMPVTHSSAAQRRGRIGRNPKNENDQYIYMGEPLENDEDC
AHWKEAKMLLDNINTPEGIIPSMFEPEREKVDAIDGEYRLRGEARKTFVDLMRRGDLPVWLAYRVAAEGI
NYADRRWCFDGVKNNQILEENVEVEIWTKEGERKKLKPRWLDARIYSDPLALKEFKEFAAGRKSLTLNLI
TEMGRLPTFMTQKARDALDNLAVLHTAEAGGRAYNHALSELPETLETLLLLTLLATVTGGIFLFLMSGRG
IGKMTLGMCCIITASILLWYAQIQPHWIAASIILEFFLIVLLIPEPEKQRTPQDNQLTYVVIAILTVVAA
TMANEMGFLEKTKKDLGLGSIATQQPESNILDIDLRPASAWTLYAVATTFVTPMLRHSIENSSVNVSLTA
IANQATVLMGLGKGWPLSKMDIGVPLLAIGCYSQVNPITLTAALFLLVAHYAIIGPGLQAKATREAQKRA
AAGIMKNPTVDGITVIDLDPIPYDPKFEKQLGQVMLLVLCVTQVLMMRTTWALCEALTLATGPISTLWEG
NPGRFWNTTIAVSMANIFRGSYLAGAGLLFSIMKNTTNTRRGTGNIGETLGEKWKSRLNALGKSEFQIYK
KSGIQEVDRTLAKEGIKRGETDHHAVSRGSAKLRWFVERNMVTPEGKVVDLGCGRGGWSYYCGGLKNVRE
VKGLTKGGPGHEEPIPMSTYGWNLVRLQSGVDVFFIPPEKCDTLLCDIGESSPNPTVEAGRTLRVLNLVE
NWLNNNTQFCIKVLNPYMPSVIEKMEALQRKYGGALVRNPLSRNSTHEMYWVSNASGNIVSSVNMISRML
INRFTMRYKKATYEPDVDLGSGTRNIGIESEIPNLDIIGKRIEKIKQEHETSWHYDQDHPYKTWAYHGSY
ETKQTGSASSMVNGVVRLLTKPWDVVPMVTQMAMTDTTPFGQQRVFKEKVDTRTQEPKEGTKKLMKITAE
WLWKELGKKKTPRMCTREEFTRKVRSNAALGAIFTDENKWKSAREAVEDSRFWELVDKERNLHLEGKCET
CVYNMMGKREKKLGEFGKAKGSRAIWYMWLGARFLEFEALGFLNEDHWFSRENSLSGVEGEGLHKLGYIL
RDVSKKEGGAMYADDTAGWDTRITLEDLKNEEMVTNHMEGEHKKLAEAIFKLTYQNKVVRVQRPTPRGTV
MDIISRRDQRGSGQVGTYGLNTFTNMEAQLIRQMEGEGVFKSIQHLTITEEIAVQNWLARVGRERLSRMA
ISGDDCVVKPLDDRFASALTALNDMGKIRKDIQQWEPSRGWNDWTQVPFCSHHFHELIMKDGRVLVVPCR
NQDELIGRARISQGAGWSLRETACLGKSYAQMWSLMYFHRRDLRLAANAICSAVPSHWVPTSRTTWSIHA
KHEWMTTEDMLTVWNRVWIQENPWMEDKTPVESWEEIPYLGKREDQWCGSLIGLTSRATWAKNIQAAINQ
VRSLIGNEEYTDYMPSMKRFRREEEEAGVLW

Molecule Role : Protective antigen
Related Vaccine(s): TAK-003

10. POLY

Gene Name : POLY
Sequence Strain (Species/Organism) : Dengue virus 1
NCBI Gene ID : 5075725
NCBI Protein GI : 9626686
Locus Tag : DV1_gp1
Genbank Accession : U88536
Protein Accession : NP_059433
Taxonomy ID : 11053
Gene Starting Position : 94
Gene Ending Position : 10272
Gene Strand (Orientation) : +
Protein Name : polyprotein
Protein pI : 8.57
Protein Weight : 356227.65
Protein Length : 3392
Protein Note : Also known as polyprotein gene

DNA Sequence : Show Sequence

>NC_001477.1:94-10272 Dengue virus 1, complete genome
GATGAACAACCAACGGAAAAAGACGGGTCGACCGTCTTTCAATATGCTGAAACGCGCGAGAAACCGCGTG
TCAACTGTTTCACAGTTGGCGAAGAGATTCTCAAAAGGATTGCTTTCAGGCCAAGGACCCATGAAATTGG
TGATGGCTTTTATAGCATTCCTAAGATTTCTAGCCATACCTCCAACAGCAGGAATTTTGGCTAGATGGGG
CTCATTCAAGAAGAATGGAGCGATCAAAGTGTTACGGGGTTTCAAGAAAGAAATCTCAAACATGTTGAAC
ATAATGAACAGGAGGAAAAGATCTGTGACCATGCTCCTCATGCTGCTGCCCACAGCCCTGGCGTTCCATC
TGACCACCCGAGGGGGAGAGCCGCACATGATAGTTAGCAAGCAGGAAAGAGGAAAATCACTTTTGTTTAA
GACCTCTGCAGGTGTCAACATGTGCACCCTTATTGCAATGGATTTGGGAGAGTTATGTGAGGACACAATG
ACCTACAAATGCCCCCGGATCACTGAGACGGAACCAGATGACGTTGACTGTTGGTGCAATGCCACGGAGA
CATGGGTGACCTATGGAACATGTTCTCAAACTGGTGAACACCGACGAGACAAACGTTCCGTCGCACTGGC
ACCACACGTAGGGCTTGGTCTAGAAACAAGAACCGAAACGTGGATGTCCTCTGAAGGCGCTTGGAAACAA
ATACAAAAAGTGGAGACCTGGGCTCTGAGACACCCAGGATTCACGGTGATAGCCCTTTTTCTAGCACATG
CCATAGGAACATCCATCACCCAGAAAGGGATCATTTTTATTTTGCTGATGCTGGTAACTCCATCCATGGC
CATGCGGTGCGTGGGAATAGGCAACAGAGACTTCGTGGAAGGACTGTCAGGAGCTACGTGGGTGGATGTG
GTACTGGAGCATGGAAGTTGCGTCACTACCATGGCAAAAGACAAACCAACACTGGACATTGAACTCTTGA
AGACGGAGGTCACAAACCCTGCCGTCCTGCGCAAACTGTGCATTGAAGCTAAAATATCAAACACCACCAC
CGATTCGAGATGTCCAACACAAGGAGAAGCCACGCTGGTGGAAGAACAGGACACGAACTTTGTGTGTCGA
CGAACGTTCGTGGACAGAGGCTGGGGCAATGGTTGTGGGCTATTCGGAAAAGGTAGCTTAATAACGTGTG
CTAAGTTTAAGTGTGTGACAAAACTGGAAGGAAAGATAGTCCAATATGAAAACTTAAAATATTCAGTGAT
AGTCACCGTACACACTGGAGACCAGCACCAAGTTGGAAATGAGACCACAGAACATGGAACAACTGCAACC
ATAACACCTCAAGCTCCCACGTCGGAAATACAGCTGACAGACTACGGAGCTCTAACATTGGATTGTTCAC
CTAGAACAGGGCTAGACTTTAATGAGATGGTGTTGTTGACAATGAAAAAAAAATCATGGCTCGTCCACAA
ACAATGGTTTCTAGACTTACCACTGCCTTGGACCTCGGGGGCTTCAACATCCCAAGAGACTTGGAATAGA
CAAGACTTGCTGGTCACATTTAAGACAGCTCATGCAAAAAAGCAGGAAGTAGTCGTACTAGGATCACAAG
AAGGAGCAATGCACACTGCGTTGACTGGAGCGACAGAAATCCAAACGTCTGGAACGACAACAATTTTTGC
AGGACACCTGAAATGCAGATTAAAAATGGATAAACTGATTTTAAAAGGGATGTCATATGTAATGTGCACA
GGGTCATTCAAGTTAGAGAAGGAAGTGGCTGAGACCCAGCATGGAACTGTTCTAGTGCAGGTTAAATACG
AAGGAACAGATGCACCATGCAAGATCCCCTTCTCGTCCCAAGATGAGAAGGGAGTAACCCAGAATGGGAG
ATTGATAACAGCCAACCCCATAGTCACTGACAAAGAAAAACCAGTCAACATTGAAGCGGAGCCACCTTTT
GGTGAGAGCTACATTGTGGTAGGAGCAGGTGAAAAAGCTTTGAAACTAAGCTGGTTCAAGAAGGGAAGCA
GTATAGGGAAAATGTTTGAAGCAACTGCCCGTGGAGCACGAAGGATGGCCATCCTGGGAGACACTGCATG
GGACTTCGGTTCTATAGGAGGGGTGTTCACGTCTGTGGGAAAACTGATACACCAGATTTTTGGGACTGCG
TATGGAGTTTTGTTCAGCGGTGTTTCTTGGACCATGAAGATAGGAATAGGGATTCTGCTGACATGGCTAG
GATTAAACTCAAGGAGCACGTCCCTTTCAATGACGTGTATCGCAGTTGGCATGGTCACACTGTACCTAGG
AGTCATGGTTCAGGCGGACTCGGGATGTGTAATCAACTGGAAAGGCAGAGAACTCAAATGTGGAAGCGGC
ATTTTTGTCACCAATGAAGTCCACACCTGGACAGAGCAATATAAATTCCAGGCCGACTCCCCTAAGAGAC
TATCAGCGGCCATTGGGAAGGCATGGGAGGAGGGTGTGTGTGGAATTCGATCAGCCACTCGTCTCGAGAA
CATCATGTGGAAGCAAATATCAAATGAATTAAACCACATCTTACTTGAAAATGACATGAAATTTACAGTG
GTCGTAGGAGACGTTAGTGGAATCTTGGCCCAAGGAAAGAAAATGATTAGGCCACAACCCATGGAACACA
AATACTCGTGGAAAAGCTGGGGAAAAGCCAAAATCATAGGAGCAGATGTACAGAATACCACCTTCATCAT
CGACGGCCCAAACACCCCAGAATGCCCTGATAACCAAAGAGCATGGAACATTTGGGAAGTTGAAGACTAT
GGATTTGGAATTTTCACGACAAACATATGGTTGAAATTGCGTGACTCCTACACTCAAGTGTGTGACCACC
GGCTAATGTCAGCTGCCATCAAGGATAGCAAAGCAGTCCATGCTGACATGGGGTACTGGATAGAAAGTGA
AAAGAACGAGACTTGGAAGTTGGCAAGAGCCTCCTTCATAGAAGTTAAGACATGCATCTGGCCAAAATCC
CACACTCTATGGAGCAATGGAGTCCTGGAAAGTGAGATGATAATCCCAAAGATATATGGAGGACCAATAT
CTCAGCACAACTACAGACCAGGATATTTCACACAAACAGCAGGGCCGTGGCACTTGGGCAAGTTAGAACT
AGATTTTGATTTATGTGAAGGTACCACTGTTGTTGTGGATGAACATTGTGGAAATCGAGGACCATCTCTT
AGAACCACAACAGTCACAGGAAAGACAATCCATGAATGGTGCTGTAGATCTTGCACGTTACCCCCCCTAC
GTTTCAAAGGAGAAGACGGGTGCTGGTACGGCATGGAAATCAGACCAGTCAAGGAGAAGGAAGAGAACCT
AGTTAAGTCAATGGTCTCTGCAGGGTCAGGAGAAGTGGACAGTTTTTCACTAGGACTGCTATGCATATCA
ATAATGATCGAAGAGGTAATGAGATCCAGATGGAGCAGAAAAATGCTGATGACTGGAACATTGGCTGTGT
TCCTCCTTCTCACAATGGGACAATTGACATGGAATGATCTGATCAGGCTATGTATCATGGTTGGAGCCAA
CGCTTCAGACAAGATGGGGATGGGAACAACGTACCTAGCTTTGATGGCCACTTTCAGAATGAGACCAATG
TTCGCAGTCGGGCTACTGTTTCGCAGATTAACATCTAGAGAAGTTCTTCTTCTTACAGTTGGATTGAGTC
TGGTGGCATCTGTAGAACTACCAAATTCCTTAGAGGAGCTAGGGGATGGACTTGCAATGGGCATCATGAT
GTTGAAATTACTGACTGATTTTCAGTCACATCAGCTATGGGCTACCTTGCTGTCTTTAACATTTGTCAAA
ACAACTTTTTCATTGCACTATGCATGGAAGACAATGGCTATGATACTGTCAATTGTATCTCTCTTCCCTT
TATGCCTGTCCACGACTTCTCAAAAAACAACATGGCTTCCGGTGTTGCTGGGATCTCTTGGATGCAAACC
ACTAACCATGTTTCTTATAACAGAAAACAAAATCTGGGGAAGGAAAAGCTGGCCTCTCAATGAAGGAATT
ATGGCTGTTGGAATAGTTAGCATTCTTCTAAGTTCACTTCTCAAGAATGATGTGCCACTAGCTGGCCCAC
TAATAGCTGGAGGCATGCTAATAGCATGTTATGTCATATCTGGAAGCTCGGCCGATTTATCACTGGAGAA
AGCGGCTGAGGTCTCCTGGGAAGAAGAAGCAGAACACTCTGGTGCCTCACACAACATACTAGTGGAGGTC
CAAGATGATGGAACCATGAAGATAAAGGATGAAGAGAGAGATGACACACTCACCATTCTCCTCAAAGCAA
CTCTGCTAGCAATCTCAGGGGTATACCCAATGTCAATACCGGCGACCCTCTTTGTGTGGTATTTTTGGCA
GAAAAAGAAACAGAGATCAGGAGTGCTATGGGACACACCCAGCCCTCCAGAAGTGGAAAGAGCAGTCCTT
GATGATGGCATTTATAGAATTCTCCAAAGAGGATTGTTGGGCAGGTCTCAAGTAGGAGTAGGAGTTTTTC
AAGAAGGCGTGTTCCACACAATGTGGCACGTCACCAGGGGAGCTGTCCTCATGTACCAAGGGAAGAGACT
GGAACCAAGTTGGGCCAGTGTCAAAAAAGACTTGATCTCATATGGAGGAGGTTGGAGGTTTCAAGGATCC
TGGAACGCGGGAGAAGAAGTGCAGGTGATTGCTGTTGAACCGGGGAAGAACCCCAAAAATGTACAGACAG
CGCCGGGTACCTTCAAGACCCCTGAAGGCGAAGTTGGAGCCATAGCTCTAGACTTTAAACCCGGCACATC
TGGATCTCCTATCGTGAACAGAGAGGGAAAAATAGTAGGTCTTTATGGAAATGGAGTGGTGACAACAAGT
GGTACCTACGTCAGTGCCATAGCTCAAGCTAAAGCATCACAAGAAGGGCCTCTACCAGAGATTGAGGACG
AGGTGTTTAGGAAAAGAAACTTAACAATAATGGACCTACATCCAGGATCGGGAAAAACAAGAAGATACCT
TCCAGCCATAGTCCGTGAGGCCATAAAAAGAAAGCTGCGCACGCTAGTCTTAGCTCCCACAAGAGTTGTC
GCTTCTGAAATGGCAGAGGCGCTCAAGGGAATGCCAATAAGGTATCAGACAACAGCAGTGAAGAGTGAAC
ACACGGGAAAGGAGATAGTTGACCTTATGTGTCACGCCACTTTCACTATGCGTCTCCTGTCTCCTGTGAG
AGTTCCCAATTATAATATGATTATCATGGATGAAGCACATTTTACCGATCCAGCCAGCATAGCAGCCAGA
GGGTATATCTCAACCCGAGTGGGTATGGGTGAAGCAGCTGCGATTTTCATGACAGCCACTCCCCCCGGAT
CGGTGGAGGCCTTTCCACAGAGCAATGCAGTTATCCAAGATGAGGAAAGAGACATTCCTGAAAGATCATG
GAACTCAGGCTATGACTGGATCACTGATTTCCCAGGTAAAACAGTCTGGTTTGTTCCAAGCATCAAATCA
GGAAATGACATTGCCAACTGTTTAAGAAAGAATGGGAAACGGGTGGTCCAATTGAGCAGAAAAACTTTTG
ACACTGAGTACCAGAAAACAAAAAATAACGACTGGGACTATGTTGTCACAACAGACATATCCGAAATGGG
AGCAAACTTCCGAGCCGACAGGGTAATAGACCCGAGGCGGTGCCTGAAACCGGTAATACTAAAAGATGGC
CCAGAGCGTGTCATTCTAGCCGGACCGATGCCAGTGACTGTGGCTAGCGCCGCCCAGAGGAGAGGAAGAA
TTGGAAGGAACCAAAATAAGGAAGGCGATCAGTATATTTACATGGGACAGCCTCTAAACAATGATGAGGA
CCACGCCCATTGGACAGAAGCAAAAATGCTCCTTGACAACATAAACACACCAGAAGGGATTATCCCAGCC
CTCTTTGAGCCGGAGAGAGAAAAGAGTGCAGCAATAGACGGGGAATACAGACTACGGGGTGAAGCGAGGA
AAACGTTCGTGGAGCTCATGAGAAGAGGAGATCTACCTGTCTGGCTATCCTACAAAGTTGCCTCAGAAGG
CTTCCAGTACTCCGACAGAAGGTGGTGCTTTGATGGGGAAAGGAACAACCAGGTGTTGGAGGAGAACATG
GACGTGGAGATCTGGACAAAAGAAGGAGAAAGAAAGAAACTACGACCCCGCTGGCTGGATGCCAGAACAT
ACTCTGACCCACTGGCTCTGCGCGAATTCAAAGAGTTCGCAGCAGGAAGAAGAAGCGTCTCAGGTGACCT
AATATTAGAAATAGGGAAACTTCCACAACATTTAACGCAAAGGGCCCAGAACGCCTTGGACAATCTGGTT
ATGTTGCACAACTCTGAACAAGGAGGAAAAGCCTATAGACACGCCATGGAAGAACTACCAGACACCATAG
AAACGTTAATGCTCCTAGCTTTGATAGCTGTGCTGACTGGTGGAGTGACGTTGTTCTTCCTATCAGGAAG
GGGTCTAGGAAAAACATCCATTGGCCTACTCTGCGTGATTGCCTCAAGTGCACTGTTATGGATGGCCAGT
GTGGAACCCCATTGGATAGCGGCCTCTATCATACTGGAGTTCTTTCTGATGGTGTTGCTTATTCCAGAGC
CGGACAGACAGCGCACTCCACAAGACAACCAGCTAGCATACGTGGTGATAGGTCTGTTATTCATGATATT
GACAGTGGCAGCCAATGAGATGGGATTACTGGAAACCACAAAGAAGGACCTGGGGATTGGTCATGCAGCT
GCTGAAAACCACCATCATGCTGCAATGCTGGACGTAGACCTACATCCAGCTTCAGCCTGGACTCTCTATG
CAGTGGCCACAACAATTATCACTCCCATGATGAGACACACAATTGAAAACACAACGGCAAATATTTCCCT
GACAGCTATTGCAAACCAGGCAGCTATATTGATGGGACTTGACAAGGGATGGCCAATATCAAAGATGGAC
ATAGGAGTTCCACTTCTCGCCTTGGGGTGCTATTCTCAGGTGAACCCGCTGACGCTGACAGCGGCGGTAT
TGATGCTAGTGGCTCATTATGCCATAATTGGACCCGGACTGCAAGCAAAAGCTACTAGAGAAGCTCAAAA
AAGGACAGCAGCCGGAATAATGAAAAACCCAACTGTCGACGGGATCGTTGCAATAGATTTGGACCCTGTG
GTTTACGATGCAAAATTTGAAAAACAGCTAGGCCAAATAATGTTGTTGATACTTTGCACATCACAGATCC
TCCTGATGCGGACCACATGGGCCTTGTGTGAATCCATCACACTAGCCACTGGACCTCTGACTACGCTTTG
GGAGGGATCTCCAGGAAAATTCTGGAACACCACGATAGCGGTGTCCATGGCAAACATTTTTAGGGGAAGT
TATCTAGCAGGAGCAGGTCTGGCCTTTTCATTAATGAAATCTCTAGGAGGAGGTAGGAGAGGCACGGGAG
CCCAAGGGGAAACACTGGGAGAAAAATGGAAAAGACAGCTAAACCAATTGAGCAAGTCAGAATTCAACAC
TTACAAAAGGAGTGGGATTATAGAGGTGGATAGATCTGAAGCCAAAGAGGGGTTAAAAAGAGGAGAAACG
ACTAAACACGCAGTGTCGAGAGGAACGGCCAAACTGAGGTGGTTTGTGGAGAGGAACCTTGTGAAACCAG
AAGGGAAAGTCATAGACCTCGGTTGTGGAAGAGGTGGCTGGTCATATTATTGCGCTGGGCTGAAGAAAGT
CACAGAAGTGAAAGGATACACGAAAGGAGGACCTGGACATGAGGAACCAATCCCAATGGCAACCTATGGA
TGGAACCTAGTAAAGCTATACTCCGGGAAAGATGTATTCTTTACACCACCTGAGAAATGTGACACCCTCT
TGTGTGATATTGGTGAGTCCTCTCCGAACCCAACTATAGAAGAAGGAAGAACGTTACGTGTTCTAAAGAT
GGTGGAACCATGGCTCAGAGGAAACCAATTTTGCATAAAAATTCTAAATCCCTATATGCCGAGTGTGGTA
GAAACTTTGGAGCAAATGCAAAGAAAACATGGAGGAATGCTAGTGCGAAATCCACTCTCAAGAAACTCCA
CTCATGAAATGTACTGGGTTTCATGTGGAACAGGAAACATTGTGTCAGCAGTAAACATGACATCTAGAAT
GCTGCTAAATCGATTCACAATGGCTCACAGGAAGCCAACATATGAAAGAGACGTGGACTTAGGCGCTGGA
ACAAGACATGTGGCAGTAGAACCAGAGGTGGCCAACCTAGATATCATTGGCCAGAGGATAGAGAATATAA
AAAATGAACACAAATCAACATGGCATTATGATGAGGACAATCCATACAAAACATGGGCCTATCATGGATC
ATATGAGGTCAAGCCATCAGGATCAGCCTCATCCATGGTCAATGGTGTGGTGAGACTGCTAACCAAACCA
TGGGATGTCATTCCCATGGTCACACAAATAGCCATGACTGACACCACACCCTTTGGACAACAGAGGGTGT
TTAAAGAGAAAGTTGACACGCGTACACCAAAAGCGAAACGAGGCACAGCACAAATTATGGAGGTGACAGC
CAGGTGGTTATGGGGTTTTCTCTCTAGAAACAAAAAACCCAGAATCTGCACAAGAGAGGAGTTCACAAGA
AAAGTCAGGTCAAACGCAGCTATTGGAGCAGTGTTCGTTGATGAAAATCAATGGAACTCAGCAAAAGAGG
CAGTGGAAGATGAACGGTTCTGGGACCTTGTGCACAGAGAGAGGGAGCTTCATAAACAAGGAAAATGTGC
CACGTGTGTCTACAACATGATGGGAAAGAGAGAGAAAAAATTAGGAGAGTTCGGAAAGGCAAAAGGAAGT
CGCGCAATATGGTACATGTGGTTGGGAGCGCGCTTTTTAGAGTTTGAAGCCCTTGGTTTCATGAATGAAG
ATCACTGGTTCAGCAGAGAGAATTCACTCAGTGGAGTGGAAGGAGAAGGACTCCACAAACTTGGATACAT
ACTCAGAGACATATCAAAGATTCCAGGGGGAAATATGTATGCAGATGACACAGCCGGATGGGACACAAGA
ATAACAGAGGATGATCTTCAGAATGAGGCCAAAATCACTGACATCATGGAACCTGAACATGCCCTATTGG
CCACGTCAATCTTTAAGCTAACCTACCAAAACAAGGTAGTAAGGGTGCAGAGACCAGCGAAAAATGGAAC
CGTGATGGATGTCATATCCAGACGTGACCAGAGAGGAAGTGGACAGGTTGGAACCTATGGCTTAAACACC
TTCACCAACATGGAGGCCCAACTAATAAGACAAATGGAGTCTGAGGGAATCTTTTCACCCAGCGAATTGG
AAACCCCAAATCTAGCCGAAAGAGTCCTCGACTGGTTGAAAAAACATGGCACCGAGAGGCTGAAAAGAAT
GGCAATCAGTGGAGATGACTGTGTGGTGAAACCAATCGATGACAGATTTGCAACAGCCTTAACAGCTTTG
AATGACATGGGAAAGGTAAGAAAAGACATACCGCAATGGGAACCTTCAAAAGGATGGAATGATTGGCAAC
AAGTGCCTTTCTGTTCACACCATTTCCACCAGCTGATTATGAAGGATGGGAGGGAGATAGTGGTGCCATG
CCGCAACCAAGATGAACTTGTAGGTAGGGCCAGAGTATCACAAGGCGCCGGATGGAGCTTGAGAGAAACT
GCATGCCTAGGCAAGTCATATGCACAAATGTGGCAGCTGATGTACTTCCACAGGAGAGACTTGAGATTAG
CGGCTAATGCTATCTGTTCAGCCGTTCCAGTTGATTGGGTCCCAACCAGCCGCACCACCTGGTCGATCCA
TGCCCACCATCAATGGATGACAACAGAAGACATGTTGTCAGTGTGGAATAGGGTTTGGATAGAGGAAAAC
CCATGGATGGAGGACAAGACTCATGTGTCCAGTTGGGAAGACGTTCCATACCTAGGAAAAAGGGAAGATC
AATGGTGTGGTTCCCTAATAGGCTTAACAGCACGAGCCACCTGGGCCACCAACATACAAGTGGCCATAAA
CCAAGTGAGAAGGCTCATTGGGAATGAGAATTATCTAGACTTCATGACATCAATGAAGAGATTCAAAAAC
GAGAGTGATCCCGAAGGGGCACTCTGGTA

Protein Sequence : Show Sequence

>NP_059433.1 polyprotein [dengue virus type I]
MNNQRKKTGRPSFNMLKRARNRVSTVSQLAKRFSKGLLSGQGPMKLVMAFIAFLRFLAIPPTAGILARWG
SFKKNGAIKVLRGFKKEISNMLNIMNRRKRSVTMLLMLLPTALAFHLTTRGGEPHMIVSKQERGKSLLFK
TSAGVNMCTLIAMDLGELCEDTMTYKCPRITETEPDDVDCWCNATETWVTYGTCSQTGEHRRDKRSVALA
PHVGLGLETRTETWMSSEGAWKQIQKVETWALRHPGFTVIALFLAHAIGTSITQKGIIFILLMLVTPSMA
MRCVGIGNRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEVTNPAVLRKLCIEAKISNTTT
DSRCPTQGEATLVEEQDTNFVCRRTFVDRGWGNGCGLFGKGSLITCAKFKCVTKLEGKIVQYENLKYSVI
VTVHTGDQHQVGNETTEHGTTATITPQAPTSEIQLTDYGALTLDCSPRTGLDFNEMVLLTMKKKSWLVHK
QWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVVVLGSQEGAMHTALTGATEIQTSGTTTIFA
GHLKCRLKMDKLILKGMSYVMCTGSFKLEKEVAETQHGTVLVQVKYEGTDAPCKIPFSSQDEKGVTQNGR
LITANPIVTDKEKPVNIEAEPPFGESYIVVGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGDTAW
DFGSIGGVFTSVGKLIHQIFGTAYGVLFSGVSWTMKIGIGILLTWLGLNSRSTSLSMTCIAVGMVTLYLG
VMVQADSGCVINWKGRELKCGSGIFVTNEVHTWTEQYKFQADSPKRLSAAIGKAWEEGVCGIRSATRLEN
IMWKQISNELNHILLENDMKFTVVVGDVSGILAQGKKMIRPQPMEHKYSWKSWGKAKIIGADVQNTTFII
DGPNTPECPDNQRAWNIWEVEDYGFGIFTTNIWLKLRDSYTQVCDHRLMSAAIKDSKAVHADMGYWIESE
KNETWKLARASFIEVKTCIWPKSHTLWSNGVLESEMIIPKIYGGPISQHNYRPGYFTQTAGPWHLGKLEL
DFDLCEGTTVVVDEHCGNRGPSLRTTTVTGKTIHEWCCRSCTLPPLRFKGEDGCWYGMEIRPVKEKEENL
VKSMVSAGSGEVDSFSLGLLCISIMIEEVMRSRWSRKMLMTGTLAVFLLLTMGQLTWNDLIRLCIMVGAN
ASDKMGMGTTYLALMATFRMRPMFAVGLLFRRLTSREVLLLTVGLSLVASVELPNSLEELGDGLAMGIMM
LKLLTDFQSHQLWATLLSLTFVKTTFSLHYAWKTMAMILSIVSLFPLCLSTTSQKTTWLPVLLGSLGCKP
LTMFLITENKIWGRKSWPLNEGIMAVGIVSILLSSLLKNDVPLAGPLIAGGMLIACYVISGSSADLSLEK
AAEVSWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTLTILLKATLLAISGVYPMSIPATLFVWYFWQ
KKKQRSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRL
EPSWASVKKDLISYGGGWRFQGSWNAGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTS
GSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRKRNLTIMDLHPGSGKTRRYL
PAIVREAIKRKLRTLVLAPTRVVASEMAEALKGMPIRYQTTAVKSEHTGKEIVDLMCHATFTMRLLSPVR
VPNYNMIIMDEAHFTDPASIAARGYISTRVGMGEAAAIFMTATPPGSVEAFPQSNAVIQDEERDIPERSW
NSGYDWITDFPGKTVWFVPSIKSGNDIANCLRKNGKRVVQLSRKTFDTEYQKTKNNDWDYVVTTDISEMG
ANFRADRVIDPRRCLKPVILKDGPERVILAGPMPVTVASAAQRRGRIGRNQNKEGDQYIYMGQPLNNDED
HAHWTEAKMLLDNINTPEGIIPALFEPEREKSAAIDGEYRLRGEARKTFVELMRRGDLPVWLSYKVASEG
FQYSDRRWCFDGERNNQVLEENMDVEIWTKEGERKKLRPRWLDARTYSDPLALREFKEFAAGRRSVSGDL
ILEIGKLPQHLTQRAQNALDNLVMLHNSEQGGKAYRHAMEELPDTIETLMLLALIAVLTGGVTLFFLSGR
GLGKTSIGLLCVIASSALLWMASVEPHWIAASIILEFFLMVLLIPEPDRQRTPQDNQLAYVVIGLLFMIL
TVAANEMGLLETTKKDLGIGHAAAENHHHAAMLDVDLHPASAWTLYAVATTIITPMMRHTIENTTANISL
TAIANQAAILMGLDKGWPISKMDIGVPLLALGCYSQVNPLTLTAAVLMLVAHYAIIGPGLQAKATREAQK
RTAAGIMKNPTVDGIVAIDLDPVVYDAKFEKQLGQIMLLILCTSQILLMRTTWALCESITLATGPLTTLW
EGSPGKFWNTTIAVSMANIFRGSYLAGAGLAFSLMKSLGGGRRGTGAQGETLGEKWKRQLNQLSKSEFNT
YKRSGIIEVDRSEAKEGLKRGETTKHAVSRGTAKLRWFVERNLVKPEGKVIDLGCGRGGWSYYCAGLKKV
TEVKGYTKGGPGHEEPIPMATYGWNLVKLYSGKDVFFTPPEKCDTLLCDIGESSPNPTIEEGRTLRVLKM
VEPWLRGNQFCIKILNPYMPSVVETLEQMQRKHGGMLVRNPLSRNSTHEMYWVSCGTGNIVSAVNMTSRM
LLNRFTMAHRKPTYERDVDLGAGTRHVAVEPEVANLDIIGQRIENIKNEHKSTWHYDEDNPYKTWAYHGS
YEVKPSGSASSMVNGVVRLLTKPWDVIPMVTQIAMTDTTPFGQQRVFKEKVDTRTPKAKRGTAQIMEVTA
RWLWGFLSRNKKPRICTREEFTRKVRSNAAIGAVFVDENQWNSAKEAVEDERFWDLVHRERELHKQGKCA
TCVYNMMGKREKKLGEFGKAKGSRAIWYMWLGARFLEFEALGFMNEDHWFSRENSLSGVEGEGLHKLGYI
LRDISKIPGGNMYADDTAGWDTRITEDDLQNEAKITDIMEPEHALLATSIFKLTYQNKVVRVQRPAKNGT
VMDVISRRDQRGSGQVGTYGLNTFTNMEAQLIRQMESEGIFSPSELETPNLAERVLDWLKKHGTERLKRM
AISGDDCVVKPIDDRFATALTALNDMGKVRKDIPQWEPSKGWNDWQQVPFCSHHFHQLIMKDGREIVVPC
RNQDELVGRARVSQGAGWSLRETACLGKSYAQMWQLMYFHRRDLRLAANAICSAVPVDWVPTSRTTWSIH
AHHQWMTTEDMLSVWNRVWIEENPWMEDKTHVSSWEDVPYLGKREDQWCGSLIGLTARATWATNIQVAIN
QVRRLIGNENYLDFMTSMKRFKNESDPEGALW

Molecule Role : Protective antigen
Related Vaccine(s): TV003/TV005

11. POLY

Gene Name : POLY
Sequence Strain (Species/Organism) : Dengue virus 4
NCBI Gene ID : 5075729
NCBI Protein GI : 12084823
Locus Tag : DV4_gp1
Genbank Accession : AF326825
Protein Accession : NP_073286
Taxonomy ID : 11070
Gene Starting Position : 101
Gene Ending Position : 10264
Gene Strand (Orientation) : +
Protein Name : polyprotein
Protein pI : 8.63
Protein Weight : 354952.36
Protein Length : 3387
Protein Note : Also known as polyprotein gene

DNA Sequence : Show Sequence

>NC_002640.1:101-10264 Dengue virus 4, complete genome
AATGAACCAACGAAAAAAGGTGGTTAGACCACCTTTCAATATGCTGAAACGCGAGAGAAACCGCGTATCA
ACCCCTCAAGGGTTGGTGAAGAGATTCTCAACCGGACTTTTTTCTGGGAAAGGACCCTTACGGATGGTGC
TAGCATTCATCACGTTTTTGCGAGTCCTTTCCATCCCACCAACAGCAGGGATTCTGAAGAGATGGGGACA
GTTGAAGAAAAATAAGGCCATCAAGATACTGATTGGATTCAGGAAGGAGATAGGCCGCATGCTGAACATC
TTGAACGGGAGAAAAAGGTCAACGATAACATTGCTGTGCTTGATTCCCACCGTAATGGCGTTTTCCCTCA
GCACAAGAGATGGCGAACCCCTCATGATAGTGGCAAAACATGAAAGGGGGAGACCTCTCTTGTTTAAGAC
AACAGAGGGGATCAACAAATGCACTCTCATTGCCATGGACTTGGGTGAAATGTGTGAGGACACTGTCACG
TATAAATGCCCCCTACTGGTCAATACCGAACCTGAAGACATTGATTGCTGGTGCAACCTCACGTCTACCT
GGGTCATGTATGGGACATGCACCCAGAGCGGAGAACGGAGACGAGAGAAGCGCTCAGTAGCTTTAACACC
ACATTCAGGAATGGGATTGGAAACAAGAGCTGAGACATGGATGTCATCGGAAGGGGCTTGGAAGCATGCT
CAGAGAGTAGAGAGCTGGATACTCAGAAACCCAGGATTCGCGCTCTTGGCAGGATTTATGGCTTATATGA
TTGGGCAAACAGGAATCCAGCGAACTGTCTTCTTTGTCCTAATGATGCTGGTCGCCCCATCCTACGGAAT
GCGATGCGTAGGAGTAGGAAACAGAGACTTTGTGGAAGGAGTCTCAGGTGGAGCATGGGTCGACCTGGTG
CTAGAACATGGAGGATGCGTCACAACCATGGCCCAGGGAAAACCAACCTTGGATTTTGAACTGACTAAGA
CAACAGCCAAGGAAGTGGCTCTGTTAAGAACCTATTGCATTGAAGCCTCAATATCAAACATAACTACGGC
AACAAGATGTCCAACGCAAGGAGAGCCTTATCTGAAAGAGGAACAGGACCAACAGTACATTTGCCGGAGA
GATGTGGTAGACAGAGGGTGGGGCAATGGCTGTGGCTTGTTTGGAAAAGGAGGAGTTGTGACATGTGCGA
AGTTTTCATGTTCGGGGAAGATAACAGGCAATTTGGTCCAAATTGAGAACCTTGAATACACAGTGGTTGT
AACAGTCCACAATGGAGACACCCATGCAGTAGGAAATGACACATCCAATCATGGAGTTACAGCCATGATA
ACTCCCAGGTCACCATCGGTGGAAGTCAAATTGCCGGACTATGGAGAACTAACACTCGATTGTGAACCCA
GGTCTGGAATTGACTTTAATGAGATGATTCTGATGAAAATGAAAAAGAAAACATGGCTCGTGCATAAGCA
ATGGTTTTTGGATCTGCCTCTTCCATGGACAGCAGGAGCAGACACATCAGAGGTTCACTGGAATTACAAA
GAGAGAATGGTGACATTTAAGGTTCCTCATGCCAAGAGACAGGATGTGACAGTGCTGGGATCTCAGGAAG
GAGCCATGCATTCTGCCCTCGCTGGAGCCACAGAAGTGGACTCCGGTGATGGAAATCACATGTTTGCAGG
ACATCTTAAGTGCAAAGTCCGTATGGAGAAATTGAGAATCAAGGGAATGTCATACACGATGTGTTCAGGA
AAGTTTTCAATTGACAAAGAGATGGCAGAAACACAGCATGGGACAACAGTGGTGAAAGTCAAGTATGAAG
GTGCTGGAGCTCCGTGTAAAGTCCCCATAGAGATAAGAGATGTAAACAAGGAAAAAGTGGTTGGGCGTAT
CATCTCATCCACCCCTTTGGCTGAGAATACCAACAGTGTAACCAACATAGAATTAGAACCCCCCTTTGGG
GACAGCTACATAGTGATAGGTGTTGGAAACAGCGCATTAACACTCCATTGGTTCAGGAAAGGGAGTTCCA
TTGGCAAGATGTTTGAGTCCACATACAGAGGTGCAAAACGAATGGCCATTCTAGGTGAAACAGCTTGGGA
TTTTGGTTCCGTTGGTGGACTGTTCACATCATTGGGAAAGGCTGTGCACCAGGTTTTTGGAAGTGTGTAT
ACAACCATGTTTGGAGGAGTCTCATGGATGATTAGAATCCTAATTGGGTTCTTAGTGTTGTGGATTGGCA
CGAACTCGAGGAACACTTCAATGGCTATGACGTGCATAGCTGTTGGAGGAATCACTCTGTTTCTGGGCTT
CACAGTTCAAGCAGACATGGGTTGTGTGGCGTCATGGAGTGGGAAAGAATTGAAGTGTGGAAGCGGAATT
TTTGTGGTTGACAACGTGCACACTTGGACAGAACAGTACAAATTTCAACCAGAGTCCCCAGCGAGACTAG
CGTCTGCAATATTAAATGCCCACAAAGATGGGGTCTGTGGAATTAGATCAACCACGAGGCTGGAAAATGT
CATGTGGAAGCAAATAACCAACGAGCTAAACTATGTTCTCTGGGAAGGAGGACATGACCTCACTGTAGTG
GCTGGGGATGTGAAGGGGGTGTTGACCAAAGGCAAGAGAGCACTCACACCCCCAGTGAGTGATCTGAAAT
ATTCATGGAAGACATGGGGAAAAGCAAAAATCTTCACCCCAGAAGCAAGAAATAGCACATTTTTAATAGA
CGGACCAGACACCTCTGAATGCCCCAATGAACGAAGAGCATGGAACTCTCTTGAGGTGGAAGACTATGGA
TTTGGCATGTTCACGACCAACATATGGATGAAATTCCGAGAAGGAAGTTCAGAAGTGTGTGACCACAGGT
TAATGTCAGCTGCAATTAAAGATCAGAAAGCTGTGCATGCTGACATGGGTTATTGGATAGAGAGCTCAAA
AAACCAGACCTGGCAGATAGAGAAAGCATCTCTTATTGAAGTGAAAACATGTCTGTGGCCCAAGACCCAC
ACACTGTGGAGCAATGGAGTGCTGGAAAGCCAGATGCTCATTCCAAAATCATATGCGGGCCCTTTTTCAC
AGCACAATTACCGCCAGGGCTATGCCACGCAAACCGTGGGCCCATGGCACTTAGGCAAATTAGAGATAGA
CTTTGGAGAATGCCCCGGAACAACAGTCACAATTCAGGAGGATTGTGACCATAGAGGCCCATCTTTGAGG
ACCACCACTGCATCTGGAAAACTAGTCACGCAATGGTGCTGCCGCTCCTGCACGATGCCTCCCTTAAGGT
TCTTGGGAGAAGATGGGTGCTGGTATGGGATGGAGATTAGGCCCTTGAGTGAAAAAGAAGAGAACATGGT
CAAATCACAGGTGACGGCCGGACAGGGCACATCAGAAACTTTTTCTATGGGTCTGTTGTGCCTGACCTTG
TTTGTGGAAGAATGCTTGAGGAGAAGAGTCACTAGGAAACACATGATATTAGTTGTGGTGATCACTCTTT
GTGCTATCATCCTGGGAGGCCTCACATGGATGGACTTACTACGAGCCCTCATCATGTTGGGGGACACTAT
GTCTGGTAGAATAGGAGGACAGATCCACCTAGCCATCATGGCAGTGTTCAAGATGTCACCAGGATACGTG
CTGGGTGTGTTTTTAAGGAAACTCACTTCAAGAGAGACAGCACTAATGGTAATAGGAATGGCCATGACAA
CGGTGCTTTCAATTCCACATGACCTTATGGAACTCATTGATGGAATATCACTGGGACTAATTTTGCTAAA
AATAGTAACACAGTTTGACAACACCCAAGTGGGAACCTTAGCTCTTTCCTTGACTTTCATAAGATCAACA
ATGCCATTGGTCATGGCTTGGAGGACCATTATGGCTGTGTTGTTTGTGGTCACACTCATTCCTTTGTGCA
GGACAAGCTGTCTTCAAAAACAGTCTCATTGGGTAGAAATAACAGCACTCATCCTAGGAGCCCAAGCTCT
GCCAGTGTACCTAATGACTCTTATGAAAGGAGCCTCAAGAAGATCTTGGCCTCTTAACGAGGGCATAATG
GCTGTGGGTTTGGTTAGTCTCTTAGGAAGCGCTCTTTTAAAGAATGATGTCCCTTTAGCTGGCCCAATGG
TGGCAGGAGGCTTACTTCTGGCGGCTTACGTGATGAGTGGTAGCTCAGCAGATCTGTCACTAGAGAAGGC
CGCCAACGTGCAGTGGGATGAAATGGCAGACATAACAGGCTCAAGCCCAATCGTAGAAGTGAAGCAGGAT
GAAGATGGCTCTTTCTCCATACGGGACGTCGAGGAAACCAATATGATAACCCTTTTGGTGAAACTGGCAC
TGATAACAGTGTCAGGTCTCTACCCCTTGGCAATTCCAGTCACAATGACCTTATGGTACATGTGGCAAGT
GAAAACACAAAGATCAGGAGCCCTGTGGGACGTCCCCTCACCCGCTGCCACTAAAAAAGCCGCACTGTCT
GAAGGAGTGTACAGGATCATGCAAAGAGGGTTATTCGGGAAAACTCAGGTTGGAGTAGGGATACACATGG
AAGGTGTATTTCACACAATGTGGCATGTAACAAGAGGATCAGTGATCTGCCACGAGACTGGGAGATTGGA
GCCATCTTGGGCTGACGTCAGGAATGACATGATATCATACGGTGGGGGATGGAGGCTTGGAGACAAATGG
GACAAAGAAGAAGACGTTCAGGTCCTCGCCATAGAACCAGGAAAAAATCCTAAACATGTCCAAACGAAAC
CTGGCCTTTTCAAGACCCTAACTGGAGAAATTGGAGCAGTAACATTAGATTTCAAACCCGGAACGTCTGG
TTCTCCCATCATCAACAGGAAAGGAAAAGTCATCGGACTCTATGGAAATGGAGTAGTTACCAAATCAGGT
GATTACGTCAGTGCCATAACGCAAGCCGAAAGAATTGGAGAGCCAGATTATGAAGTGGATGAGGACATTT
TTCGAAAGAAAAGATTAACTATAATGGACTTACACCCCGGAGCTGGAAAGACAAAAAGAATTCTTCCATC
AATAGTGAGAGAAGCCTTAAAAAGGAGGCTACGAACTTTGATTTTAGCTCCCACGAGAGTGGTGGCGGCC
GAGATGGAAGAGGCCCTACGTGGACTGCCAATCCGTTATCAGACCCCAGCTGTGAAATCAGAACACACAG
GAAGAGAGATTGTAGACCTCATGTGTCATGCAACCTTCACAACAAGACTTTTGTCATCAACCAGGGTTCC
AAATTACAACCTTATAGTGATGGATGAAGCACATTTCACCGATCCTTCTAGTGTCGCGGCTAGAGGATAC
ATCTCGACCAGGGTGGAAATGGGAGAGGCAGCAGCCATCTTCATGACCGCAACCCCTCCCGGAGCGACAG
ATCCCTTTCCCCAGAGCAACAGCCCAATAGAAGACATCGAGAGGGAAATTCCGGAAAGGTCATGGAACAC
AGGGTTCGACTGGATAACAGACTACCAAGGGAAAACTGTGTGGTTTGTTCCCAGCATAAAAGCTGGAAAT
GACATTGCAAATTGTTTGAGAAAGTCGGGAAAGAAAGTTATCCAGTTGAGTAGGAAAACCTTTGATACAG
AGTATCCAAAAACGAAACTCACGGACTGGGACTTTGTGGTCACTACAGACATATCTGAAATGGGGGCCAA
TTTTAGAGCCGGGAGAGTGATAGACCCTAGAAGATGCCTCAAGCCAGTTATCCTACCAGATGGGCCAGAG
AGAGTCATTTTAGCAGGTCCTATTCCAGTGACTCCAGCAAGCGCTGCTCAGAGAAGAGGGCGAATAGGAA
GGAACCCAGCACAAGAAGACGACCAATACGTTTTCTCCGGAGACCCACTAAAAAATGATGAAGATCATGC
CCACTGGACAGAAGCAAAGATGCTGCTTGACAATATCTACACCCCAGAAGGGATCATTCCAACATTGTTT
GGTCCGGAAAGGGAAAAAACCCAAGCCATTGATGGAGAGTTTCGCCTCAGAGGGGAACAAAGGAAGACTT
TTGTGGAATTAATGAGGAGAGGAGACCTTCCGGTGTGGCTGAGCTATAAGGTAGCTTCTGCTGGCATTTC
TTACGAAGATCGGGAATGGTGCTTCACAGGGGAAAGAAATAACCAAATTTTAGAAGAAAACATGGAGGTT
GAAATTTGGACTAGAGAGGGAGAAAAGAAAAAGCTAAGGCCAAGATGGTTAGATGCACGTGTATACGCTG
ACCCCATGGCTTTGAAGGATTTCAAGGAGTTTGCCAGTGGAAGGAAGAGTATAACTCTCGACATCCTAAC
AGAGATTGCCAGTTTGCCAACTTACCTTTCCTCTAGGGCCAAGCTCGCCCTTGATAACATAGTCATGCTC
CACACAACAGAAAGAGGAGGGAGGGCCTATCAACACGCCCTGAACGAACTTCCGGAGTCACTGGAAACAC
TCATGCTTGTAGCTTTACTAGGTGCTATGACAGCAGGCATCTTCCTGTTTTTCATGCAAGGGAAAGGAAT
AGGGAAATTGTCAATGGGTTTGATAACCATTGCGGTGGCTAGTGGCTTGCTCTGGGTAGCAGAAATTCAA
CCCCAGTGGATAGCGGCCTCAATCATACTAGAGTTTTTTCTCATGGTACTGTTGATACCGGAACCAGAAA
AACAAAGGACCCCACAAGACAATCAATTGATCTACGTCATATTGACCATTCTCACCATCATTGGTCTAAT
AGCAGCCAACGAGATGGGGCTGATTGAAAAAACAAAAACGGATTTTGGGTTTTACCAGGTAAAAACAGAA
ACCACCATCCTCGATGTGGACTTGAGACCAGCTTCAGCATGGACGCTCTATGCAGTAGCCACCACAATTC
TGACTCCCATGCTGAGACACACCATAGAAAACACGTCGGCCAACCTATCTCTAGCAGCCATTGCCAACCA
GGCAGCCGTCCTAATGGGGCTTGGAAAAGGATGGCCGCTCCACAGAATGGACCTCGGTGTGCCGCTGTTA
GCAATGGGATGCTATTCTCAAGTGAACCCAACAACCTTGACAGCATCCTTAGTCATGCTTTTAGTCCATT
ATGCAATAATAGGCCCAGGATTGCAGGCAAAAGCCACAAGAGAGGCCCAGAAAAGGACAGCTGCTGGGAT
CATGAAAAATCCCACAGTGGACGGGATAACAGTAATAGATCTAGAACCAATATCCTATGACCCAAAATTT
GAAAAGCAATTAGGGCAGGTCATGCTACTAGTCTTGTGTGCTGGACAACTACTCTTGATGAGAACAACAT
GGGCTTTCTGTGAAGTCTTGACTTTGGCCACAGGACCAATCTTGACCTTGTGGGAGGGCAACCCGGGAAG
GTTTTGGAACACGACCATAGCCGTATCCACCGCCAACATTTTCAGGGGAAGTTACTTGGCGGGAGCTGGA
CTGGCTTTTTCACTCATAAAGAATGCACAAACCCCTAGGAGGGGAACTGGGACCACAGGAGAGACACTGG
GAGAGAAGTGGAAGAGACAGCTAAACTCATTAGACAGAAAAGAGTTTGAAGAGTATAAAAGAAGTGGAAT
ACTAGAAGTGGACAGGACTGAAGCCAAGTCTGCCCTGAAAGATGGGTCTAAAATCAAGCATGCAGTATCA
AGAGGGTCCAGTAAGATCAGATGGATTGTTGAGAGAGGGATGGTAAAGCCAAAAGGGAAAGTTGTAGATC
TTGGCTGTGGGAGAGGAGGATGGTCTTATTACATGGCGACACTCAAGAACGTGACTGAAGTGAAAGGGTA
TACAAAAGGAGGTCCAGGACATGAAGAACCGATTCCCATGGCTACTTATGGTTGGAATTTGGTCAAACTC
CATTCAGGGGTTGACGTGTTCTACAAACCCACAGAGCAAGTGGACACCCTGCTCTGTGATATTGGGGAGT
CATCTTCTAATCCAACAATAGAGGAAGGAAGAACATTAAGAGTTTTGAAGATGGTGGAGCCATGGCTCTC
TTCAAAACCTGAATTCTGCATCAAAGTCCTTAACCCCTACATGCCAACAGTCATAGAAGAGCTGGAGAAA
CTGCAGAGAAAACATGGTGGGAACCTTGTCAGATGCCCGCTGTCCAGGAACTCCACCCATGAGATGTATT
GGGTGTCAGGAGCGTCGGGAAACATTGTGAGCTCTGTGAACACAACATCAAAGATGTTGTTGAACAGGTT
CACAACAAGGCATAGGAAACCCACTTATGAGAAGGACGTAGATCTTGGGGCAGGAACGAGAAGTGTCTCC
ACTGAAACAGAAAAACCAGACATGACAATCATTGGGAGAAGGCTTCAGCGATTGCAAGAAGAGCACAAAG
AAACCTGGCATTATGATCAGGAAAACCCATACAGAACCTGGGCGTATCATGGAAGCTATGAAGCTCCTTC
GACAGGCTCTGCATCCTCCATGGTGAACGGGGTGGTAAAACTGCTAACAAAACCCTGGGATGTGATTCCA
ATGGTGACTCAGTTAGCCATGACAGATACAACCCCTTTTGGGCAACAAAGAGTGTTCAAAGAGAAGGTGG
ATACCAGAACACCACAACCAAAACCCGGTACACGAATGGTTATGACCACGACAGCCAATTGGCTGTGGGC
CCTCCTTGGAAAGAAGAAAAATCCCAGACTGTGCACAAGGGAAGAGTTCATCTCAAAAGTTAGATCAAAC
GCAGCCATAGGCGCAGTCTTTCAGGAAGAACAGGGATGGACATCAGCCAGTGAAGCTGTGAATGACAGCC
GGTTTTGGGAACTGGTTGACAAAGAAAGGGCCCTACACCAGGAAGGGAAATGTGAATCGTGTGTCTATAA
CATGATGGGAAAACGTGAGAAAAAGTTAGGAGAGTTTGGCAGAGCCAAGGGAAGCCGAGCAATCTGGTAC
ATGTGGCTGGGAGCGCGGTTTCTGGAATTTGAAGCCCTGGGTTTTTTGAATGAAGATCACTGGTTTGGCA
GAGAAAATTCATGGAGTGGAGTGGAAGGGGAAGGTCTGCACAGATTGGGATATATCCTGGAGGAGATAGA
CAAGAAGGATGGAGACCTAATGTATGCTGATGACACAGCAGGCTGGGACACAAGAATCACTGAGGATGAC
CTTCAAAATGAGGAACTGATCACGGAACAGATGGCTCCCCACCACAAGATCCTAGCCAAAGCCATTTTCA
AACTAACCTATCAAAACAAAGTGGTGAAAGTCCTCAGACCCACACCGCGGGGAGCGGTGATGGATATCAT
ATCCAGGAAAGACCAAAGAGGTAGTGGACAAGTTGGAACATATGGTTTGAACACATTCACCAACATGGAA
GTTCAACTCATCCGCCAAATGGAAGCTGAAGGAGTCATCACACAAGATGACATGCAGAACCCAAAAGGGT
TGAAAGAAAGAGTTGAGAAATGGCTGAAAGAGTGTGGTGTCGACAGGTTAAAGAGGATGGCAATCAGTGG
AGACGATTGCGTGGTGAAGCCCCTAGATGAGAGGTTTGGCACTTCCCTCCTCTTCTTGAACGACATGGGA
AAGGTGAGGAAAGACATTCCGCAGTGGGAACCATCTAAGGGATGGAAAAACTGGCAAGAGGTTCCTTTTT
GCTCCCACCACTTTCACAAGATCTTTATGAAGGATGGCCGCTCACTAGTTGTTCCATGTAGAAACCAGGA
TGAACTGATAGGGAGAGCCAGAATCTCGCAGGGAGCTGGATGGAGCTTAAGAGAAACAGCCTGCCTGGGC
AAAGCTTACGCCCAGATGTGGTCGCTTATGTACTTCCACAGAAGGGATCTGCGTTTAGCCTCCATGGCCA
TATGCTCAGCAGTTCCAACGGAATGGTTTCCAACAAGCAGAACAACATGGTCAATCCACGCTCATCACCA
GTGGATGACCACTGAAGATATGCTCAAAGTGTGGAACAGAGTGTGGATAGAAGACAACCCTAATATGACT
GACAAGACTCCAGTCCATTCGTGGGAAGATATACCTTACCTAGGGAAAAGAGAGGATTTGTGGTGTGGAT
CCCTGATTGGACTTTCTTCCAGAGCCACCTGGGCGAAGAACATTCATACGGCCATAACCCAGGTCAGGAA
CCTGATCGGAAAAGAGGAATACGTGGATTACATGCCAGTAATGAAAAGATACAGTGCTCCTTCAGAGAGT
GAAGGAGTTCTGTA

Protein Sequence : Show Sequence

>NP_073286.1 polyprotein [Dengue virus type 4]
MNQRKKVVRPPFNMLKRERNRVSTPQGLVKRFSTGLFSGKGPLRMVLAFITFLRVLSIPPTAGILKRWGQ
LKKNKAIKILIGFRKEIGRMLNILNGRKRSTITLLCLIPTVMAFSLSTRDGEPLMIVAKHERGRPLLFKT
TEGINKCTLIAMDLGEMCEDTVTYKCPLLVNTEPEDIDCWCNLTSTWVMYGTCTQSGERRREKRSVALTP
HSGMGLETRAETWMSSEGAWKHAQRVESWILRNPGFALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYGM
RCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAKEVALLRTYCIEASISNITTA
TRCPTQGEPYLKEEQDQQYICRRDVVDRGWGNGCGLFGKGGVVTCAKFSCSGKITGNLVQIENLEYTVVV
TVHNGDTHAVGNDTSNHGVTAMITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHKQ
WFLDLPLPWTAGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMFAG
HLKCKVRMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTVVKVKYEGAGAPCKVPIEIRDVNKEKVVGRI
ISSTPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRGAKRMAILGETAWD
FGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVLWIGTNSRNTSMAMTCIAVGGITLFLGF
TVQADMGCVASWSGKELKCGSGIFVVDNVHTWTEQYKFQPESPARLASAILNAHKDGVCGIRSTTRLENV
MWKQITNELNYVLWEGGHDLTVVAGDVKGVLTKGKRALTPPVSDLKYSWKTWGKAKIFTPEARNSTFLID
GPDTSECPNERRAWNSLEVEDYGFGMFTTNIWMKFREGSSEVCDHRLMSAAIKDQKAVHADMGYWIESSK
NQTWQIEKASLIEVKTCLWPKTHTLWSNGVLESQMLIPKSYAGPFSQHNYRQGYATQTVGPWHLGKLEID
FGECPGTTVTIQEDCDHRGPSLRTTTASGKLVTQWCCRSCTMPPLRFLGEDGCWYGMEIRPLSEKEENMV
KSQVTAGQGTSETFSMGLLCLTLFVEECLRRRVTRKHMILVVVITLCAIILGGLTWMDLLRALIMLGDTM
SGRIGGQIHLAIMAVFKMSPGYVLGVFLRKLTSRETALMVIGMAMTTVLSIPHDLMELIDGISLGLILLK
IVTQFDNTQVGTLALSLTFIRSTMPLVMAWRTIMAVLFVVTLIPLCRTSCLQKQSHWVEITALILGAQAL
PVYLMTLMKGASRRSWPLNEGIMAVGLVSLLGSALLKNDVPLAGPMVAGGLLLAAYVMSGSSADLSLEKA
ANVQWDEMADITGSSPIVEVKQDEDGSFSIRDVEETNMITLLVKLALITVSGLYPLAIPVTMTLWYMWQV
KTQRSGALWDVPSPAATKKAALSEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLE
PSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSG
SPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERIGEPDYEVDEDIFRKKRLTIMDLHPGAGKTKRILPS
IVREALKRRLRTLILAPTRVVAAEMEEALRGLPIRYQTPAVKSEHTGREIVDLMCHATFTTRLLSSTRVP
NYNLIVMDEAHFTDPSSVAARGYISTRVEMGEAAAIFMTATPPGATDPFPQSNSPIEDIEREIPERSWNT
GFDWITDYQGKTVWFVPSIKAGNDIANCLRKSGKKVIQLSRKTFDTEYPKTKLTDWDFVVTTDISEMGAN
FRAGRVIDPRRCLKPVILPDGPERVILAGPIPVTPASAAQRRGRIGRNPAQEDDQYVFSGDPLKNDEDHA
HWTEAKMLLDNIYTPEGIIPTLFGPEREKTQAIDGEFRLRGEQRKTFVELMRRGDLPVWLSYKVASAGIS
YEDREWCFTGERNNQILEENMEVEIWTREGEKKKLRPRWLDARVYADPMALKDFKEFASGRKSITLDILT
EIASLPTYLSSRAKLALDNIVMLHTTERGGRAYQHALNELPESLETLMLVALLGAMTAGIFLFFMQGKGI
GKLSMGLITIAVASGLLWVAEIQPQWIAASIILEFFLMVLLIPEPEKQRTPQDNQLIYVILTILTIIGLI
AANEMGLIEKTKTDFGFYQVKTETTILDVDLRPASAWTLYAVATTILTPMLRHTIENTSANLSLAAIANQ
AAVLMGLGKGWPLHRMDLGVPLLAMGCYSQVNPTTLTASLVMLLVHYAIIGPGLQAKATREAQKRTAAGI
MKNPTVDGITVIDLEPISYDPKFEKQLGQVMLLVLCAGQLLLMRTTWAFCEVLTLATGPILTLWEGNPGR
FWNTTIAVSTANIFRGSYLAGAGLAFSLIKNAQTPRRGTGTTGETLGEKWKRQLNSLDRKEFEEYKRSGI
LEVDRTEAKSALKDGSKIKHAVSRGSSKIRWIVERGMVKPKGKVVDLGCGRGGWSYYMATLKNVTEVKGY
TKGGPGHEEPIPMATYGWNLVKLHSGVDVFYKPTEQVDTLLCDIGESSSNPTIEEGRTLRVLKMVEPWLS
SKPEFCIKVLNPYMPTVIEELEKLQRKHGGNLVRCPLSRNSTHEMYWVSGASGNIVSSVNTTSKMLLNRF
TTRHRKPTYEKDVDLGAGTRSVSTETEKPDMTIIGRRLQRLQEEHKETWHYDQENPYRTWAYHGSYEAPS
TGSASSMVNGVVKLLTKPWDVIPMVTQLAMTDTTPFGQQRVFKEKVDTRTPQPKPGTRMVMTTTANWLWA
LLGKKKNPRLCTREEFISKVRSNAAIGAVFQEEQGWTSASEAVNDSRFWELVDKERALHQEGKCESCVYN
MMGKREKKLGEFGRAKGSRAIWYMWLGARFLEFEALGFLNEDHWFGRENSWSGVEGEGLHRLGYILEEID
KKDGDLMYADDTAGWDTRITEDDLQNEELITEQMAPHHKILAKAIFKLTYQNKVVKVLRPTPRGAVMDII
SRKDQRGSGQVGTYGLNTFTNMEVQLIRQMEAEGVITQDDMQNPKGLKERVEKWLKECGVDRLKRMAISG
DDCVVKPLDERFGTSLLFLNDMGKVRKDIPQWEPSKGWKNWQEVPFCSHHFHKIFMKDGRSLVVPCRNQD
ELIGRARISQGAGWSLRETACLGKAYAQMWSLMYFHRRDLRLASMAICSAVPTEWFPTSRTTWSIHAHHQ
WMTTEDMLKVWNRVWIEDNPNMTDKTPVHSWEDIPYLGKREDLWCGSLIGLSSRATWAKNIHTAITQVRN
LIGKEEYVDYMPVMKRYSAPSESEGVL

Molecule Role : Protective antigen

12. prM from Dengue virus 1

Gene Name : prM from Dengue virus 1
Sequence Strain (Species/Organism) : Dengue virus 1
NCBI Protein GI : 18308046
Other Database IDs : CDD:279856
CDD:279358
Taxonomy ID : 11053
Gene Strand (Orientation) : ?
Protein Name : premembrane
Protein pI : 5.16
Protein Weight : 11796.33
Protein Length : 161
Protein Note : Flavivirus polyprotein propeptide; pfam01570

Protein Sequence : Show Sequence

>AAL67809.1 premembrane, partial [Dengue virus 1]
FHLTTRGGEPHMIVSKQERGKSLLFKTSAGVNMCTLIAMDLGELCEDTMTYKCPRITEAEPDDVDCWCNA
TDTWVTYGTCSQTGEHRRDKRSVALAPHVGLGLETRTE

Molecule Role : Protective antigen
Related Vaccine(s): CAdVax-Den12/Den34 , Dengue virus DNA vaccine D1ME encoding prM and E , Dengue Virus DNA Vaccine D1ME-VRP , Dengvaxia , TAK-003

13. prM from Dengue virus 2

Gene Name : prM from Dengue virus 2
Sequence Strain (Species/Organism) : Dengue virus 2
NCBI Protein GI : 18308058
Other Database IDs : CDD:279856
CDD:279358
Taxonomy ID : 11060
Gene Strand (Orientation) : ?
Protein Name : premembrane
Protein pI : 6.34
Protein Weight : 13464.2
Protein Length : 172
Protein Note : Flavivirus polyprotein propeptide; pfam01570

Protein Sequence : Show Sequence

>AAL67815.1 premembrane, partial [Dengue virus 2]
FHLTTRNGEPHMIVSRQEKGKSLLFKTKDGTNMCTLMAMDLGELCEDTITYKCPFLKQNEPEDIDCWCNS
TSTWVTYGTCTTTGEHRREKRSVALVPHVGMGLETRTETWMSSEGAWKH

Molecule Role : Protective antigen
Related Vaccine(s): Dengue virus DNA vaccine 1040D2MEL encoding dengue-2 prM-E-LAMP chimeric protein , Dengue virus DNA vaccine p1012D2ME encoding prM and E from DEN 2 New Guinea C strain , Dengue virus DNA vaccine sA encoding prM and E from Dengue Virus 4 , Dengue virus DNA vaccine sABC encoding prM and E , Dengue virus DNA vaccine sC encoding prM and E , Dengvaxia , TAK-003

14. prM from Dengue virus 3

Gene Name : prM from Dengue virus 3
Sequence Strain (Species/Organism) : Dengue virus 3
NCBI Protein GI : 18308070
Other Database IDs : CDD:279856
CDD:279358
Taxonomy ID : 11069
Gene Strand (Orientation) : ?
Protein Name : premembrane
Protein pI : 5.57
Protein Weight : 12139.72
Protein Length : 163
Protein Note : Flavivirus polyprotein propeptide; pfam01570

Protein Sequence : Show Sequence

>AAL67821.1 premembrane, partial [Dengue virus 3]
FHLTSRDGEPRMIVGKNERGKSLLFKTASGINMCTLIAMDLGEMCDDTVTYKCPHITEVEPEDIDCWCNL
TSTWVTYGTCNQAGEHRRDKRSVALAPHVGMGLDTRTQTW

Molecule Role : Protective antigen
Related Vaccine(s): CAdVax-Den12/Den34 , Dengvaxia , TAK-003

15. prM from Dengue virus 4

Gene Name : prM from Dengue virus 4
VO ID : VO_0011315
NCBI Protein GI : 18308086
Other Database IDs : CDD:279856
CDD:279358
Taxonomy ID : 11070
Gene Strand (Orientation) : ?
Protein Name : premembrane
Protein Length : 184
Protein Note : Flavivirus polyprotein propeptide; pfam01570

Protein Sequence : Show Sequence

>AAL67829.1 premembrane, partial [Dengue virus 4]
FHLSTRDGEPLMIVAKHERGRPLLFKTTEGINKCTLIAMDLGEMCEDTVTYKCPLLVNTEPEDIDCWCNL
TSTWVMYGTCPQSGERRREKRSVALTPHSGMGLETRAETWMSSEGAWKHAQRVESWILRNP

Molecule Role : Protective antigen
Molecule Role Annotation : A recombinant vaccinia virus that expressed the pre-M protein of Dengue 4 virus was constructed. Mice immunized with the recombinant virus were protected against subsequent dengue 4 encephalitis challenge (Bray and Lai, 1991).
Related Vaccine(s): Dengue Vaccine using Vaccinia Virus expressing prM Protein , Dengue Virus DNA Vaccine expressing prM/E proteins , Dengvaxia , TAK-003

III. Vaccine Related Host Genes

1. Il12a

Gene Name : Il12a
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 16159
NCBI Protein GI : 226874945
Genbank Accession : AC121306
Protein Accession : NP_001152896
Taxonomy ID : 10090
Chromosome No : 3
Gene Starting Position : 68690643
Gene Ending Position : 68698546
Gene Strand (Orientation) : +
Protein Name : transcript variant 1
Protein pI : 8.33
Protein Weight : 25111.9
Protein Length : 236
Protein Note : Also known as p35; Ll12a; Il-12a; IL-12p35; MGC151228; MGC151232

DNA Sequence : Show Sequence

>gi|372099107:68690643-68698546 Mus musculus strain C57BL/6J chromosome 3, GRCm38 C57BL/6J
CTGCCACCTACTCCCTTGGATCTGAGCTGGACCCTTGCATCTGGCGTCTACACTGCTGCTGAAATCTTCT
CACCGTGCACATCCAAGGATATCTCTATGGTAAAAGTCCAGAAAGGCTAAAGATGTTGTCCACAATCTCT
CGGCAATGACCAGATATATCCCCACCAGTATCACAACTTGCAACGCGCTCCGTTCCCATCTGCCCTCTGC
CTCCCTACTGTGTTGATTCCCATTTCCAAAACTAGCTCAGAATGCATCCCACTGGCAGCCAGGCAATGCC
TTCTTGCAGATCTGGAGGCTTCAGGAGCCTTTGCTGCCTCTTAGGCTCCTGCAGAGAGATGGCCTTGCTC
TCTCTGGGCCCTTTTCCCCCAAGATGCTGTGCAGTCGTCTCACTAAATCAAAACTGCCAGAACTGAGTTT
TAAGCGATATATAGCCACCACATCTATTTTGTTCCTTTATACTTTCAAAGTAGGACAGATTCGCAAAATA
CATTGAGTCAGACTCAGTGTCCACGATGGAGAGACGAGTGGGTAGCTTGTGCTTCTTTAGAAGGGGCACT
GGGCAGCGTGTTAGGGCTAGGGGGTAGTGGGGCAGGACAGACCTGTCCCGGGACAAGAGTGGCTACTCGC
AGGCCGGTTTTGCTTTCGCTCTGAGTGTGGTGGGCGGTGGGACGGTCCCGAATCTCCTCAAACGGGCACT
CCGAGAGTTAATTCGAAAGCGCCACCAGCCTTGGGGGCGATCGACGCACTTGTCCTTGAGATGTAGAGAC
AGAGAGAGAAAGCAAGAGACACAGTCCTGGGAAAGTCCTGCCGGCTATCCAGACAATTATAAAAATGTGT
CTCCCAAGGTCAGCGTTCCAACAGCCTCACCCTCGGCATCCAGCAGCTCCTCTCAGTGCCGGTCCAGCAT
GTGTCAATCACGCTGTAAGTACCTGAGGGCCGGGACCAGGGTGACTTGATGAGAGGAGAAGGCTTGAGAA
AGAACAGACAGAAGCCCTGGACCCATTAAGGGAGACTAAAGGGCTGCCAGCAACTGCAGGCCAAGGGAAG
GAAGAGGGGAAAGATGGTCGTGCTAGATTGCGCTGCACCGAGCATGGTCTCATTATAGAACAACCCTGGG
GGCTACGGCTATGCCCGTTTCACAGAAGAGAACTAAAGCCCAGCCTTGAAACCAATGTAAGGAAAATGCA
GGTCTCAGGCAGTCCCCAAACAAGATCTGGGAGGTCTTGCTTCATCTGTCAGCCCCGGGGAAGGGCTTAA
ATTATGTGTGGAGGGAGGTCAGTACCCAGAATGGATGGAAAAAATTGCCAGAATGGCTGAAGAAAGAGGC
AGGTCAAAACCAAGTTGACAAGCTCCACCTGCCCTTTGTTTCCCTTCCAGACCTCCTCTTTTTGGCCACC
CTTGCCCTCCTAAACCACCTCAGTTTGGCCAGGGTCATTCCAGTCTCTGGACCTGCCAGGTGTCTTAGCC
AGTCCCGAAACCTGCTGAAGACCACAGATGACATGGTGAAGACGGTGAGTTTCTCCTGTCCTTCTGGCTT
CAAAGTTCCGCTGTTGACATGACTTCTAACCTATCTGGTATCTGCTGGGAAGTTTATGGTATCTGGCAGG
AACCGTAGAGGGTTTCAAGACTTCTAAATATAATCTAAAGGAAACTGTGTCTCTAGAGAAAGGAAGAATG
GTAATAAATTGTAACGGCATCGGTTTAGGCTGTGTCTACACAGAGGAAAGTGGGGACTTGCAATGTCCCT
CCCAGCCTGCCTGCCTGTGTGACACAGTGTCAGGTGCTCCCTGCTTCTGCTTCAGGGCAGGTGGAACAGG
GAGACAGTCTCTAGGTACACTCTCTGTGCTTCACAAGCCATAGAGATGAATTAGATTGTCTCTCCCCCTG
CTCACCAGTGTCCAGCACTGTGATGCAGTCCCTTGTCGGATGGACACATGTCAGGGAGGACTCAGACATC
AGATAGCAAGCAGGTCCAGCCTCCAGTTTTCTGGGGCAAGTGTGATCCAGTTTTAGTCACGGCTCCACTC
ATTTTTCTCAGGTTTCATGTTTGAATGCAAAATAGCCTTTTCCGTTGTAAAATTGCCACGGTTTCCTCTC
GCTTTGGGGACAAAGCTACAGCAAAATGCTAATGTGTTTGAGATATCCTGCAGCTGCTAGGGCTGGAGAT
CCAGTAGAATTCTGGCTTAATTATGAATGGGTCTCCCGGGTTCTATCCCCCAACAGAGCGTGCGTTCATA
AGCACCTGGGAACAGAGGAGGGAAGGAGGGAAACTCTGTCTTCCTGTTTTGTTTTTAAATCTTTCTTGAG
GATCTTCTAGCTTGTTGTCTTATGGCTATCCCAACATAAGCTCCGCTCCACAAGCCCTTCTTGGTGAATT
TTCTTTCTTTCCTTCCCGTCTTGCATAACGTGCTGCTGGCTGTTCCTCCAAGCTCAGTCTTAATTGAGTG
GGGTTCCCAGGAGGGAGAGATGGCTCTGTGGTTAAGAGAGCTGGCTGCTCTTCCAGAGGTCCAGAGTTTC
CACACCCTCATGGTGGCTCACAATCATGGTAACTCTGATCATAGGGAACCTGTCGTTTTCTCTGTGCCTC
TGTGGGCACTGAGCACATGCCACACAGACATCCATGCAGGCAGAACACTCTTGGCCATGAAACCTTAAAA
TGAAGGAGAAACCTTACGAGAGGTTCCCTAAGGAATCCCTGCAGAAGGGAGAGATTGTTTTCCTAAGATG
AGGTTTGGTGTGGAGGGGATGAGGTATTCAAAGTTAACTAGCCGCTCCTCACTCCTCTGCTGCCAAATAC
CAGCACTGGGCTTCGAGACACAATAGAATTCGACCTTGTTTTCGTTTGGGTCACTATTGCTCTCTAGTTG
AACACGGAATCCACGGGGGCACATTGCTGTCTGTCCTTTGTCACACCCCAGGACCACAGCTGCATGGAAA
AGTCATCGCAGGCTTCAGTCAGAGAGCTGTTGACTTCCTAATATGTTGTGTAATTCTGTTCAGTGGTGCT
TTCCAGCACACCAGGGAATAAGAGACAGTCCCCGCGTATGTAAATTAAAGCTCAACTAGTATTTAGGGCT
TGCAAGTTTGTTACAGCCATCAAGCTGTGACTTTAACAGTTTCCTCTTTAGAAGTTAAACTTGAAAAAAA
ATAGAGGGAGAGAGAGATTCACAGGGCACAGCTGCTTGGAAAAAGGAAAAGCCACAGGACTCACCAGAAG
CAAGCAGCACAGTGTGGCACTGATGCTGATGAGTACAGCCTGCTGCACCCCAGTGTTCACATGGTGAAAA
AAATACCCTGCTGGCGGACAGCCTAGGCAAAGGGGGAGGAGAGTAGGGAGAGCGTGCGGGAGGTTGGGTT
TCTTAGCTTATGAAGAGCCTGAGTTTCCTACAGGCCAAAGAGATGACGGTTCAGAGTGGCCAGCCTAGGC
TCTGCTGATCCACTGCGATGCAGGTCTCAGAGGGAACCAGCTGTCTTGCTGAGAGATTCACCTCAGCTTC
TCCTTATGTTTTTCCCAGGCCAGAGAAAAACTGAAACATTATTCCTGCACTGCTGAAGACATCGATCATG
AAGACATCACACGGGACCAAACCAGCACATTGAAGACCTGTTTACCACTGGAACTACACAAGGTATGGAG
GACCCCCACCCAAAAAACAACAACAACAACAACAAAAAACACAATTAAGAGCCGTGCAGCCAACCTCAGC
TGTCTCCAGATACTTACTTGTAGCTATCAAACGTGAGAGTTTTGAAGAAAAAAAAAAAAGTCAACAACCA
TACAAATACTTCTACAAGCTGAAGGATATACTCGGTAACTAGGAGGTGGCTATGGTGGTATAGACCTTTA
ATTCCAGCACTTGATGGATAGAGGAAGGCCGGCTCCTGTTAAGTTAGAGGCCAGTCAGGGATACACAGCA
AGATTTCATCTTTAAAAAGAAAGGGGGTGGTGTGGCGGGTGAAGCTTACTTATTGAAGTGCTCATGTCAC
AAGCCTGGGGACCTAAGTTCCCATCCCCAGCACCCATGTAGGAGCTGGGTGTGATGGTTTCACATGCAGA
GACAGGAGGATACCTGGGCCAGCTAGTCTAGCCGAATCCATGAGCTGCAGGCCCAGTGAGAGAACCTGTA
TCAGAAAACAAGAAAGTCAGGAGAGCGGCTGAGAAAGACCCCAAAGATCATCCTCCGATTTCCACGAGTA
CATGCACCTGCACACACGTGCACACAGGAATCCTATACATAGCCACCCAAAAGCAGTTATGATGGTGAAG
TTTCTTTTACTGGAATGAAAAGTTAGTTTGAGAAAAAAATATCAGAGAGATTTATATTAAGAGTGAATGG
GTGGGGGGTATGCATGCCTTTAATCTCAGCACTTGATAGGCAGAGGCAGATGGATCTCTGTGAGTTCAAG
GCCGGCCTGGTCTACAGAGTAAGTTCCAGGACAGCCAGTGCTACAATAGAAACAGGTGATGGTGATGATG
GTGATGATGGCGGTGATGATGATGATGATGACGAAGACAAACTCCTCGGTTTATGATTTTCTTCTAGAAC
GAGAGTTGCCTGGCTACTAGAGAGACTTCTTCCACAACAGTAAGTAAGCACTCTAAGGGTTCCTTCCCCA
TGACGGATTCATAACACTGATGCCTGGTCATTCTTTCTCTAGAGAGGGAGCTGCCTGCCCCCACAGAAGA
CGTCTTTGATGATGGTAAGCCACATCACTTTTCTGAAATGCAGCAGGGTCCTGTAGTTCCAGCCCATCTC
AATGATTCCTTGCCCATTGTGTCCTGCGCTCTAGACCCTGTGCCTTGGTAGCATCTATGAGGACTTGAAG
ATGTACCAGACAGAGTTCCAGGCCATCAACGCAGCACTTCAGAATCACAACCATCAGCAGATCATTCTAG
ACAAGGGCATGCTGGTGGCCATCGATGAGCTGATGCAGGTAAGCCTTCCTCCTATCAGCCAGCGCTCCTT
TTCCATGGTGAAGAGAGGTCCTTTATTAGATATGATAAAATCAGCACAGCTTGGGTTGGGAGAGACCTGA
ACACCCCCACCCCACCCCACACCCTCATCCCCCAACCATGAAAGGCCTTGCAAGGTTACATTTGCTTAGA
GAGCCTTGAGGGGGCCTCTACAATAAGGGCAAATGCAAGCAGCCTTCTACTTGTTGACTCATGATACAAA
TCAGGCACTTTTCAAATGCTTCTTCTCATACCATCCCCACAACAAGCAAATAAGGTCTCTACAGAGGAGG
AAACTGAAGCTTAAGAGGATGAACGAGGGTTCCCTACAAAAGGGTTTTTTGTTGTTTGGTTTGGTTTGGT
TTGGTTTGGTTTGGTTTGGTTTTTCCGAGACAGGGTTTCTCTGTATAGCCCTGGCTGTCCTGGAACTCAC
TTTGTAGATCAGGCTGGCCTCGAACTCAGAACTCCACCTGCCTCTGCCTCCCAAGTGCTGGGATTAAAGG
TGTGCGCCACCATTGCCCAGCTTATTGTTGTTTTAAATACATTCTTTTCTTAAAGGTTCAAGATTAGGAC
TGGAGAGACAGTCCGATGATTAAGAGGACTTGAGTTTGGCCTGGGGCTCCTATGTAACAAACAGGGTGTG
GTCCTGAACTGCTCTCTAACTCCAGAGAGTGGAGACAGGAGGCCTATGGAGGCTTTCTTGCTGCAAGTTT
AGCCATGAAATCTCCAGGTTCAGGGAGAAAGCATGCCTCAAAGAAATAAGATGGAGAGTCACGTGATCTC
TTCTCTGGCTTCTGCATGGTGTAGGCACAGATATGCACATGTTTGAGTGCATACAATACAGGCAAACATA
CACGTGTCCTTTTTAAAATGTATAGGATGGACATTCTAGGGGCTGCACACATATTCAAATATTACTAGGG
GAAGCACTTGGGGCTGGTGTCCAAGTATAATCTATTTTGAACCAAAATGTGACCAAAATGAAAAGTGGTC
TTACATCTAGGTAATTACAGTGTTAGGTATCCGTGGGAACTTTGCTGTACCACCAGTAACACAAAGCACA
GGAGTGTGCACACCAGAGACAAGCACCTTGGCAACCAAGGCGTGGGATGAACATATGTTCAGAAGTCACT
GCCTGGAAAGCAATTGTTTTTCATTTCATACATACTGTCTTGCACAGGGTTTCTATGTCTTAGATAAAAT
ATCATGACGGAAAGCAAGTTGGGGAGGAAAGGGTTTATTTCATCTTGTAGAGTGTAGTGAGTCTATTACC
CAGGGAAGTGGAGGCAGAAGCTGATGCTGGAGAGGACTCCTGGTGACTGGAGTGCTCCACATGACTTGCT
CAGTGTGCTTTGTATAGCACCCAGGACCACCAGGCTAGGGTGAGCTGGTGCCTCCCACATCAACTGTCAA
TCAAGAAAATCACCAGAGGCTTGCCCACTGGCCAATCTGGCTGGAGGTGTTTTTCTCAATGACCACAGGC
TTGTGTAGAGTTAACATAAAAGCACCCAGGACATTACATATTGCCAGATGACTCCTTTGAAAGACAGTGA
AGTTTATGCAGGTCAAACAACCTATCATGTAGAGATTTGTAATGGATATTGCATGAACAAGGCCAGAAGT
CAGGTGATTTGGATAGTAGGAAGAGGTCTACCAGGGACCAGCCAACTATGCTGACAGGGTTAACTCTTGT
CAGCCTGTTTGTAAAATAAGATGACTTTAAATAGCCTATGTCTCTCTTGAGATTTTTGTGAGGAGCAAGC
AAAAATCTTAAACATCACAGAAACCTAAGTTCTTATTCTATGTTATGAAATCAAAGGATCGAGTGGGGAA
ACACGGTACTGGCTTGTTTATCTACCACAAATAGCGTTTCTATCAGAGATAGGTCTGTTGTTGATAATAA
GCTCTAATCCATAGATCCTACTTACCCTCCAACTCCCTCCTCTAAAAGAACAGGACTTCTTAACATAATT
TATAAAAATTAATTAGCTATTGCTGCAGGTGCTACCTCATAGACTCACACCTTCTGAGAGATCAGCTCTA
ATGACAATTTCTTTCTGGAAAATTTAGGGGTCTTGTCAGAGATCATTAAAAACATAGGTATATGCTCACA
AAAGAGTATTTCTTCCCTCTTTTCCTGCAGGAACACAGCAGGAGTAGATGTGAAATGGGTCTAGGAGTGT
GATGAGGGGCTAGGTTGCAGGCCCTGGACTTTGCATTGACTGTCTCCCATTTTGCAGACAAACATTCTAA
TTTTTAAATTGTGCATATGCTATGCTTGGTGTTTCTTTCTAGTCTCTGAATCATAATGGCGAGACTCTGC
GCCAGAAACCTCCTGTGGGAGAAGCAGACCCTTACAGAGTGAAAATGAAGCTCTGCATCCTGCTTCACGC
CTTCAGCACCCGCGTCGTGACCATCAACAGGGTGATGGGCTATCTGAGCTCCGCCTGAAAGGCTCAAGGC
CCTCTGCCACAGCGCCCTCCTCACACAGATAGGAAACAAAGAAAGATTCATAAGAGTCAGGTGGTCTTGG
CCTGGTGGGCCTTAAGCTCCTTCAGGAATCTGTTCTCCCATCACATCTCATCTCCCCAAAGGTGGCACAG
CTACCTCAGCATGGTCCCCTCCATCGCTTCTCTCATATTCACTATACAAGTTGTTTGTAAGTTTTCATCA
AAATATTGTTAAGGGGCGAAGACGTCCTCCCCTCAATGTGTTAGCAGAAGAGCAAGAACTGATAAGCTAT
TGTTTTTGTGCCAAAGTGTTTATGAAAACACTCAGTCACCCCTTATTTAAAAATATTTATTGCTATATTT
TATACTCATGAAAGTACATGAGCCTATTTATATTTATTTATTTTCTATTTATTATAATATTTCTTATCAG
ATGAATTTGAAACATTTTGAAACATACCTTATTTTGTGGTTCTAATAAAGTAATGTTATCACTT

Protein Sequence : Show Sequence

>gi|226874945|ref|NP_001152896.1| interleukin-12 subunit alpha isoform 1 [Mus musculus]
MVSVPTASPSASSSSSQCRSSMCQSRYLLFLATLALLNHLSLARVIPVSGPARCLSQSRNLLKTTDDMVK
TAREKLKHYSCTAEDIDHEDITRDQTSTLKTCLPLELHKNESCLATRETSSTTRGSCLPPQKTSLMMTLC
LGSIYEDLKMYQTEFQAINAALQNHNHQQIILDKGMLVAIDELMQSLNHNGETLRQKPPVGEADPYRVKM
KLCILLHAFSTRVVTINRVMGYLSSA

Molecule Role : Vaximmutor
Related Vaccine(s): Dengue DNA Vaccine encoding NS1 Protein

IV. Vaccine Information

1. CAdVax-Den12/Den34

a. Vaccine Ontology ID:

VO_0004643

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Baboon

e. Preparation

using a complex adenovirus vector, by incorporating the genes expressing premembrane (prM) and envelope (E) proteins of dengue virus types 1 and 2 (dengue-1 and -2, respectively) (CAdVax-Den12) or dengue-3 and -4 (CAdVax-Den34) (Raviprakash et al., 2008).

f. Immunization Route

Intramuscular injection (i.m.)

g. Macaque Response

Vaccination Protocol: Rhesus macaques were vaccinated by intramuscular inoculation of a tetravalent dengue vaccine formulated by combining the two bivalent vaccine constructs (Raviprakash et al., 2008).
Vaccine Immune Response Type: VO_0003057
Challenge Protocol: The ability of the vaccine to induce rapid, as well as sustained, protective immune responses was examined with two separate live-virus challenges administered at 4 and 24 weeks after the final vaccination (Raviprakash et al., 2008).
Efficacy: For both of these virus challenge studies, significant protection from viremia was demonstrated for all four dengue virus serotypes in vaccinated animals. Viremia from dengue-1 and dengue-3 challenges was completely blocked, whereas viremia from dengue-2 and dengue-4 was significantly reduced, as well as delayed, compared to that of control-vaccinated animals (Raviprakash et al., 2008).

2. Dengue DNA Vaccine encoding NS1 Protein

a. Vaccine Ontology ID:

VO_0011454

b. Type:

DNA vaccine

c. Status:

Research

d. Gene Engineering of NS1

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

e. Vector:

pcDNA3 (Wu et al., 2003)

f. Immunization Route

Intramuscular injection (i.m.)

g. Mouse Response

Host Strain: C57/BL6, Balb/c, and C3H
Vaccination Protocol: Groups of 3–4 weeks old female C3H mice were initially immunized with 80 μg of recombinant DNA pD2NS1, or pcDNA3 as a control. Recombinant pD2NS1 in PBS, control pcDNA3 in PBS, or PBS buffer alone was intramuscularly (i.m.) injected into the mouse thighs; the mice were subsequently boosted twice using the same method at 1 week interval (Wu et al., 2003).
Challenge Protocol: One week after the final boost, mice were i.v. challenged with 5×10^6 plaque-forming units of PL046 in 100 μl PBS. The mice after virus challenge were monitored daily for morbidity and mortality for weeks (Wu et al., 2003).
Efficacy: Intravenously challenged by lethal DEN-2, mice vaccinated with NS1-DNA exhibited a delay onset of paralysis, a marked decrease of morbidity, and a significant enhancement of survival (Wu et al., 2003).

3. Dengue Subunit E Protein Vaccine

a. Vaccine Ontology ID:

VO_0011457

b. Type:

Subunit vaccine

c. Status:

Research

d. Gene Engineering of E protein from Dengue Virus 2

Type: Recombinant protein preparation
Description: Baculovirus was used to generate the recombinant protein (Delenda et al., 1994).
Detailed Gene Information: Click here.

e. Adjuvant:

VO ID: VO_0000139

f. Adjuvant:

VO ID: VO_0000142

g. Vector:

Baculovirus (Delenda et al., 1994)

h. Immunization Route

Intraperitoneal injection (i.p.)

i. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Three-week-old female BALB/c mice were immunized by intraperitoneal injection on days 1,7, 21 and 56 with 200 gl of baculovirus infected Sf9 cell lysates (CL) or concentrated supernatant fluids (SF) supplemented with complete Freund adjuvant for the first and with incomplete Freund adjuvant for the three other injections.
Challenge Protocol: Mice were challenged withDEN-2 virus (Delenda et al., 1994).
Efficacy: Sixty eight percent (P < 0.001) of mice vaccinated with 5 gg of extracellular D2EA102 protein were protected against lethal challenge (Delenda et al., 1994).

4. Dengue Vaccine using Vaccinia Virus expressing M Protein

a. Vaccine Ontology ID:

VO_0011455

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Gene Engineering of M protein

Type: Recombinant vector construction
Description:
Detailed Gene Information: Click here.

e. Vector:

Vaccinia virus (Bray and Lai, 1991).

f. Immunization Route

Intraperitoneal injection (i.p.)

g. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: BALB/c mice were immunized by i .p .inoculation of 107 p .f .u . of recombinant vaccinia virus expressing M protein (Bray and Lai, 1991).
Challenge Protocol: The mice were challenged at age 6 weeks by intracardiac (i.c.) challenge of 100 LD50 of D4 virus, then observed 21 days for signs of encephalitis or death (Bray and Lai, 1991).
Efficacy: Mice immunized with the recombinant virus were protected against subsequent dengue 4 encephalitis challenge (Bray and Lai, 1991).

5. Dengue Vaccine using Vaccinia Virus expressing prM Protein

a. Vaccine Ontology ID:

VO_0011452

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Gene Engineering of prM from Dengue virus 4

Type: Recombinant vector construction
Description:
Detailed Gene Information: Click here.

e. Vector:

Vaccinia virus (Bray and Lai, 1991).

f. Immunization Route

Intraperitoneal injection (i.p.)

g. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: BALB/c mice were immunized by i .p .inoculation of 10^7 p .f .u . of recombinant vaccinia virus (Bray and Lai, 1991).
Challenge Protocol: The mice were challenged at age 6 weeks by i .c challenge of 100 LD50 of D4 virus, then observed 21 days for signs of encephalitis or death (Bray and Lai, 1991).
Efficacy: Mice immunized with the recombinant virus were protected against subsequent dengue 4 encephalitis challenge (Bray and Lai, 1991).

6. Dengue virus DNA vaccine 1040D2MEL encoding dengue-2 prM-E-LAMP chimeric protein

a. Vaccine Ontology ID:

VO_0004473

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Antigen

E, prM, and LAMP from dengue virus 2 New Guinea C (Raviprakash et al., 2001)

f. Gene Engineering of prM from Dengue virus 2

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

g. Gene Engineering of E protein from Dengue Virus 2

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

h. Vector:

pVR1040(Vical Inc.) (Raviprakash et al., 2001)

i. Immunization Route

Intramuscular injection (i.m.)

j. Mouse Response

Vaccine Immune Response Type: VO_0000286
Efficacy: When injected into mice, D2MEL elicited an enhanced antibody response compared to D2ME, which was further augmented by coimmunization with a plasmid expressing mouse granulocyte-monocyte colony stimulating factor (GM-CSF). Neutralizing antibodies are thought to be of paramount importance for protection against dengue disease (Raviprakash et al., 2001).

7. Dengue virus DNA vaccine D1ME encoding prM and E

a. Vaccine Ontology ID:

VO_0004470

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Monkey

e. Gene Engineering of E from Dengue virus 1

Type: DNA vaccine construction
Description: Vector pVR1012 expressed the dengue-1 pre-membrane (prM) and full-length envelope (E) genes (Raviprakash et al., 2000).
Detailed Gene Information: Click here.

f. Gene Engineering of prM from Dengue virus 1

Type: DNA vaccine construction
Description: Vector pVR1012 (Vical Inc.) expressed the dengue-1 pre-membrane (prM) and full-length envelope (E) genes (Raviprakash et al., 2000).
Detailed Gene Information: Click here.

g. Vector:

pVR1012 (Vical Inc.) (Raviprakash et al., 2000)

h. Immunization Route

Intramuscular injection (i.m.)

i. Monkey Response

Vaccine Immune Response Type: VO_0000286
Efficacy: Four of the eight i.m.-inoculated monkeys were protected completely from developing viraemia when challenged 4 months after the last dose with homologous dengue virus. The other four monkeys had reduced viraemia compared with the control immunized monkeys. The i.d. -inoculated monkeys showed no reduction in viraemia when challenged with the virus (Raviprakash et al., 2000).

8. Dengue Virus DNA Vaccine D1ME-VRP

a. Vaccine Ontology ID:

VO_0004548

b. Type:

DNA vaccine

c. Status:

Research

d. Gene Engineering of prM from Dengue virus 1

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

e. Gene Engineering of E from Dengue virus 1

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Vector:

D1ME-DNA (Chen et al., 2007)

g. Immunization Route

Intramuscular injection (i.m.)

h. Baboon Response

Vaccination Protocol: Monkeys were divided into groups DDD, VVV, DDV, and control and immunized with D1ME-DNA or D1ME-VRP as shown in the study design. D1ME-DNA was administered intramuscularly, with 0.5 ml given in each of the two upper arms. D1ME-VRP was delivered intramuscularly, as well (Chen et al., 2007).
Vaccine Immune Response Type: VO_0003057
Immune Response: After the third dose of vaccine, all animals in the DDD group, VVV group, and DDV group had developed neutralizing antibodies. The dengue virus 1-specific IgG response to all vaccination regimens was predominantly of the IgG1 type, with smaller amounts of IgG2 and no measurable amounts of IgG4 (Chen et al., 2007).
Challenge Protocol: Twenty weeks after the final immunization, animals were challenged by subcutaneous injection of 10^5 PFU of live dengue virus 1 (Western Pacific 74 strain) in a 0.5-ml volume (Chen et al., 2007).
Efficacy: All vaccination regimens showed significant protection from viremia compared to that of the unvaccinated control group (Chen et al., 2007).

9. Dengue Virus DNA Vaccine encoding NS1

a. Vaccine Ontology ID:

VO_0004549

b. Type:

DNA vaccine

c. Status:

Research

d. Antigen

NS1 from dengue virus 2 strain NGC (Costa et al., 2006)

e. Gene Engineering of NS1

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Vector:

pcTPANS1 (Costa et al., 2006)

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Vaccination Protocol: Male Balb/c mice, 4–6 weeks old, were intramuscularly injected in each hind limb tibialis anterior muscle with 50 μg of the pcTPANS1 or pcDNA3 plasmids dissolved in 50 μl of PBS (100 μg/dose/mice). Mice were inoculated with two DNA doses, given two weeks apart, and bled before immunization and 4 weeks after the first DNA dose (Costa et al., 2006).
Vaccine Immune Response Type: VO_0003057
Immune Response: All Balb/c mice intramuscularly inoculated with the pcTPANS1 presented high levels of NS1-specifc antibodies (Costa et al., 2006).
Challenge Protocol: Two weeks after the second DNA dose, each immunized mouse was challenged with intracerebral inoculation with 30 μL of 4.32 log10 PFU of DENV2 (Costa et al., 2006).
Efficacy: Vaccinated animals were challenged with intracerebral DENV-2 virus inoculations and a 100% survival was observed (Costa et al., 2006).

10. Dengue Virus DNA Vaccine expressing prM/E proteins

a. Vaccine Ontology ID:

VO_0004547

b. Type:

DNA vaccine

c. Status:

Research

d. Antigen

prM and E proteins from dengue virus 4 strain H241 (Lima et al., 2011)

e. Gene Engineering of prM from Dengue virus 4

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Gene Engineering of E from Dengue virus 4

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

g. Vector:

DENV-4-DNAv (Lima et al., 2011)

h. Immunization Route

Intramuscular injection (i.m.)

i. Mouse Response

Vaccination Protocol: Ten 5-week-old female BALB/c mice per immunization group were inoculated three times into the quadriceps muscle with 100 μg of DENV-4-DNAv or pCI (empty vector), DENV-4 heat inactivated (1 × 10^5 PFU), or PBS. The mice were primed on day 0 and boosted 15 and 30 days after the initial inoculation (Lima et al., 2011).
Vaccine Immune Response Type: VO_0003057
Immune Response: The animals immunized with DENV-4-DNAv produced rising levels, after each vaccine inoculation, of specific neutralizing antibodies against dengue-4 virus (Lima et al., 2011).
Challenge Protocol: Fifteen days after the third inoculation, the mice were challenged intracerebrally with a dose of 100LD50, prepared from a DENV-4-infected suckling mouse brain. Mouse mortality was monitored daily for 21 days (Lima et al., 2011).
Efficacy: Immunization with DENV-4-DNAv induced significant protection against DENV-4 challenge, where 80% of the challenged mice survived (Lima et al., 2011).

11. Dengue virus DNA vaccine p1012D2ME encoding prM and E from DEN 2 New Guinea C strain

a. Vaccine Ontology ID:

VO_0004474

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of E protein from Dengue Virus 2

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Gene Engineering of prM from Dengue virus 2

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

g. Vector:

pVR1012 (Vical Inc, San Diego, CA) (Porter et al., 1998)

h. Immunization Route

Intramuscular injection (i.m.)

i. Mouse Response

Vaccine Immune Response Type: VO_0000286
Efficacy: In a lethal mouse intracerebral challenge model, the vaccine provided a significant level of protection. Sixty percent of the mice immunized with the DEN DNA vaccine plus pUC 19 survived the challenge compared to only 10% in the control group that received vector plus pUC (Porter et al., 1998).

12. Dengue virus DNA vaccine pcTPANS1 encoding NS1 fused to the tissue plasminogen activator signal sequence

a. Vaccine Ontology ID:

VO_0004472

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of NS1

Type: DNA vaccine construction
Description: Vector pcDNA3 expressed the secretory signal sequence derived from human tissue plasminogen activator (t-PA) fused to the full length of the DENV-2 NS1 gene (Costa et al., 2006).
Detailed Gene Information: Click here.

f. Vector:

pcDNA3 (Costa et al., 2006)

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Vaccine Immune Response Type: VO_0000286
Efficacy: Vaccinated animals were challenged against DENV-2 in two murine models, based on intracerebral (i.c.) and intraperitoneal (i.p.) virus inoculations, and in both cases, pcTPANS1-immunized mice were protected (Costa et al., 2006).

13. Dengue virus DNA vaccine pE1D2 encoding E from Dengue Virus 2 strain New Guinea C

a. Vaccine Ontology ID:

VO_0004471

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of E protein from Dengue Virus 2

Type: DNA vaccine construction
Description: Vector pcTPA plasmid , a modified pcDNA3 vector (Invitrogen) expressed amino acids 1–398 of the E protein (Azevedo et al., 2011).
Detailed Gene Information: Click here.

f. Vector:

pcTPA plasmid , a modified pcDNA3 vector (Invitrogen) (Azevedo et al., 2011)

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Vaccine Immune Response Type: VO_0000286
Efficacy: All pE1D2-vaccinated mice survived challenge, while 45% of animals immunized with the pE2D2 died after infection. Furthermore, only 10% of pE1D2-immunized mice presented some clinical signs of infection after challenge, whereas most of animals inoculated with the pE2D2 showed effects of the disease with high morbidity degrees (Azevedo et al., 2011).

14. Dengue virus DNA vaccine sA encoding prM and E from Dengue Virus 4

a. Vaccine Ontology ID:

VO_0004466

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Macaque

e. Gene Engineering of E protein from Dengue Virus 2

Type: DNA vaccine construction
Description: Vector pMV10.1 expressed prM and E genes in which the N-terminal 90% of E gene was shuffled (Raviprakash et al., 2006).
Detailed Gene Information: Click here.

f. Gene Engineering of prM from Dengue virus 2

Type: DNA vaccine construction
Description: Vector pMV10.1 expressed prM and E genes in which the N-terminal 90% of E gene was shuffled (Raviprakash et al., 2006).
Detailed Gene Information: Click here.

g. Vector:

pMV10.1 (Raviprakash et al., 2006)

h. Immunization Route

Intramuscular injection (i.m.)

i. Macaque Response

Vaccine Immune Response Type: VO_0000286
Immune Response: Five of six animals vaccinated developed antibodies that neutralized all 4 dengue serotypes in vitro (Raviprakash et al., 2006).
Efficacy: When challenged with live dengue-1 or dengue-2 virus, partial protection against dengue-1 was observed (Raviprakash et al., 2006).

15. Dengue virus DNA vaccine sABC encoding prM and E

a. Vaccine Ontology ID:

VO_0004469

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Macaque

e. Gene Engineering of E protein from Dengue Virus 2

Type: DNA vaccine construction
Description: Vector pMV10.1 expressed premembrane and envelope genes of each of four serotypes of dengue viruses (Raviprakash et al., 2006).
Detailed Gene Information: Click here.

f. Gene Engineering of prM from Dengue virus 2

Type: DNA vaccine construction
Description: Vector pMV10.1 expressed premembrane and envelope genes of each of four serotypes of dengue viruses (Raviprakash et al., 2006).
Detailed Gene Information: Click here.

g. Gene Engineering of 18H6 synthetic E protein

Type: DNA vaccine construction
Description: This combination vaccine encoded all the proteins from all 3 vaccines (Raviprakash et al., 2006).
Detailed Gene Information: Click here.

h. Vector:

pMV10.1 (Raviprakash et al., 2006)

i. Immunization Route

Intramuscular injection (i.m.)

j. Macaque Response

Vaccine Immune Response Type: VO_0000286
Efficacy: When challenged with live dengue-1 or dengue-2 virus, partial protection against dengue-1 was observed. The best protection against dengue-1 viremia was demonstrated by the mixture of shuffled vaccines (sABC) out of all the vaccines tested (Raviprakash et al., 2006).

16. Dengue virus DNA vaccine sB encoding E

a. Vaccine Ontology ID:

VO_0004467

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Macaque

e. Gene Engineering of 18H6 synthetic E protein

Type: DNA vaccine construction
Description: Vector pMV10.1 expressed a shuffled truncated E protein (Raviprakash et al., 2006).
Detailed Gene Information: Click here.

f. Vector:

pMV10.1 (Raviprakash et al., 2006)

g. Immunization Route

Intramuscular injection (i.m.)

h. Macaque Response

Vaccine Immune Response Type: VO_0000286
Efficacy: When challenged with live dengue-1 or dengue-2 virus, partial protection against dengue-1 was observed (Raviprakash et al., 2006).

17. Dengue virus DNA vaccine sC encoding prM and E

a. Vaccine Ontology ID:

VO_0004468

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Macaque

e. Gene Engineering of E protein from Dengue Virus 2

Type: DNA vaccine construction
Description: Vector pMV10.1 expressed prM and E genes in which the N-terminal 90% of E gene was shuffled.a shuffled truncated E protein (Raviprakash et al., 2006).
Detailed Gene Information: Click here.

f. Gene Engineering of prM from Dengue virus 2

Type: DNA vaccine construction
Description: Vector pMV10.1 expressed prM and E genes in which the N-terminal 90% of E gene was shuffled.a shuffled truncated E protein (Raviprakash et al., 2006).
Detailed Gene Information: Click here.

g. Vector:

pMV10.1 (Raviprakash et al., 2006)

h. Immunization Route

Intramuscular injection (i.m.)

i. Macaque Response

Vaccine Immune Response Type: VO_0000286
Immune Response: Four of six animals vaccinated developed antibodies that neutralized all 4 dengue serotypes in vitro (Raviprakash et al., 2006).
Efficacy: When challenged with live dengue-1 or dengue-2 virus, partial protection against dengue-1 was observed (Raviprakash et al., 2006).

18. Dengue Virus Vaccine TV005

a. Type:

Live, attenuated vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

None

d. Host Species as Laboratory Animal Model:

Human

e. Antigen

Live attenuated tetravalent dengue vaccine TV005 composed of rDEN1Δ30, rDEN2/4Δ30, rDEN3Δ30/31, and rDEN4Δ30. (Hou et al., 2022)

f. Preparation

TV005 is an admixture composed of 4 DENV strains attenuated by a 30-nucleotide deletion in the 3′ UTR (rDEN1Δ30 and rDEN4Δ30), one 30-nucleotide and one-31 nucleotide deletion in the 3′ UTR (rDEN3Δ30/31), or by replacing the prM and E of rDEN4Δ30 with those of DENV2 NGC (rDEN2/4Δ30). (Hou et al., 2022)

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

Live attenuated tetravalent vaccine TV005 protects humans against DEN2Δ30 (Tonga/74) challenge. (Hou et al., 2022)

19. Dengvaxia

a. Product Name:

Dengvaxia®

b. Manufacturer:

Sanofi Pasteur

c. Type:

Recombinant vector vaccine

d. Status:

Licensed

e. Location Licensed:

immunization implementation has been limited to subnational public health programs in Brazil and the Philippines

f. Host Species for Licensed Use:

Human

g. Gene Engineering of prM from Dengue virus 1

Type: Recombinant vector construction
Description:
Detailed Gene Information: Click here.

h. Gene Engineering of prM from Dengue virus 2

Type: Recombinant vector construction
Description:
Detailed Gene Information: Click here.

i. Gene Engineering of prM from Dengue virus 3

Type: Recombinant vector construction
Description:
Detailed Gene Information: Click here.

j. Gene Engineering of prM from Dengue virus 4

Type: Recombinant vector construction
Description:
Detailed Gene Information: Click here.

k. Gene Engineering of E from Dengue virus 1

Type: Recombinant vector construction
Description:
Detailed Gene Information: Click here.

l. Gene Engineering of E protein from Dengue Virus 2

Type: Recombinant vector construction
Description:
Detailed Gene Information: Click here.

m. Gene Engineering of E from Dengue virus 3

Type: Recombinant vector construction
Description:
Detailed Gene Information: Click here.

n. Gene Engineering of E from Dengue virus 4

Type: Recombinant vector construction
Description:
Detailed Gene Information: Click here.

o. Gene Engineering of POLY

Type: Recombinant vector construction
Description: Dengvaxia® is a live attenuated tetravalent vaccine consisting of chimeras made up of structural pre-membrane (prM) and envelope (E) genes of the four DENV types combined with the nonstructural genes of yellow fever 17D vaccine strain. (Thomas and Yoon, 2019)
Detailed Gene Information: Click here.

p. Preservative:

none

q. Immunization Route

Intramuscular injection (i.m.)

r . Approved Age for Licensed Use

(Thomas and Yoon, 2019) Only people with evidence of a past dengue infection should be vaccinated based on an antibody test, or on a documented laboratory confirmed dengue infection in the past. The vaccine should be used within the indicated age range, which in most countries is 9–45 years. The age group to target for vaccination depends on the dengue transmission intensity in a given country;

s. Description

Dengvaxia® is a live attenuated tetravalent vaccine consisting of chimeras made up of structural pre-membrane (prM) and envelope (E) genes of the four DENV types combined with the nonstructural genes of yellow fever 17D vaccine strain (chimeric yellow fever dengue – CYD) (Thomas and Yoon, 2019)

t. Human Response

Vaccination Protocol: Healthy children between the ages of 9 and 16 years received three injections of recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) or placebo at months 0, 6, and 12 under blinded conditions. (Villar et al., 2015)
Immune Response: All groups were compared to the control group, Statistically significant difference in antibodies for all serotypes for month 7 and month 13 after injection was investigated. The results showed no statistically significant difference in antibodies for all serotypes at baseline (Villar et al., 2015).
Side Effects: Four serious adverse events were deemed to be vaccine-related by investigators and sponsors: three in the vaccine group (a moderate asthma attack 16 hours after the first injection, allergic urticaria 4 hours after the second injection, and acute peripheral polyneuropathy associated with viral meningitis 3 days after the first injection, without detectable vaccine virus in samples, unspecified seizures 18 hours after the first injection, without detectable vaccine virus in samples,). All children recovered fully without sequelae. (Villar et al., 2015)
Efficacy: Vaccine Efficacy for 176 cases of virologically confirmed dengue in the vaccine group and 221 in the control group that were diagnosed more than 28 days after the third dose (primary outcome): Serotype 1: 50.3%, Serotype 2: 42.3% , Serotype 3: 74.0%, Serotype 4: 77.7%. Vaccine Efficacy for all children who received at least one injection from month 0 to month 25: Serotype 1: 54.8%, Serotype 2: 50.2%, Serotype 3: 74.2%, Serotype 4: 80.9% (Villar et al., 2015).

20. rMV-TDV

a. Type:

Recombinant vector vaccine

b. Status:

Research

c. Host Species for Licensed Use:

None

d. Antigen

Bivalent fusion envelope protein domain III (ED3) of DENV-1,2,3,4 (Lin et al., 2020)

e. Gene Engineering of E from Dengue virus 1

Type: Recombinant vector construction
Description: domain 3 (Lin et al., 2020)
Detailed Gene Information: Click here.

f. Gene Engineering of E protein from Dengue Virus 2

Type: Recombinant vector construction
Description: domain 3 (Lin et al., 2020)
Detailed Gene Information: Click here.

g. Gene Engineering of E from Dengue virus 3

Type: Recombinant protein preparation
Description: domain 3 (Lin et al., 2020)
Detailed Gene Information: Click here.

h. Gene Engineering of E from Dengue virus 4

Type: Recombinant vector construction
Description: domain 3 (Lin et al., 2020)
Detailed Gene Information: Click here.

i. Vector:

Measles virus (Lin et al., 2020)

j. Immunization Route

Intraperitoneal injection (i.p.)

k. Description

rMV-TDV consists of two recombinant MV vectors carrying the genes encoding bivalent fusion envelope protein domain III (ED3) of DENV-1 and -3 or DENV-2 and -4. (Lin et al., 2020)

l. Mouse Response

Vaccination Protocol: Groups of 6-8-week-old AG-hCD46 mice were immunized intraperitoneally with rMV-TDV, a mixture containing 1 × 10^5 pfu of rMV-D13 and 1 × 10^5 pfu of rMV-D24, or 2 × 10^5 pfu of rMV-EGFP for the control. Mice were boosted with the same recombinant viruses and doses four weeks later. (Lin et al., 2020)
Immune Response: A significant ED3-specific IgG response was induced after a single injection of rMV-TDV, but it was not observed in rMV-EGFP-immunized mice, and the response reached peak titers after the boost and was maintained at a high level for at least 20 weeks. A significant increase in neutralizing antibody titers (NT) to the 4 DENV serotypes was observed in rMV-TDV-immunized mice 8 weeks after vaccination compared to the rMV-EGFP controls. Only rMV-TDV- but not rMV-EGFP-immunized mice showed an obvious increase in the ED3-specific IFN-γ response dominated by DENV-3 after a single injection. Even 5 or 20 weeks later, the significantly higher level of DENV-3-specific IFN-γ responses were still maintained in rMV-TDV-immunized mice compared to the rMV-EGFP group. DENV-specific IL-4 responses were almost undetectable even after the boost. (Lin et al., 2020)
Challenge Protocol: Mice were challenged 4 weeks after the last immunization by subcutaneously injecting 1.5 × 107 ffu of wild-type DENV-2/16681. (Lin et al., 2020)
Efficacy: . Consistent with the higher viremia and IFN-γ increase, TNF-α but not IL-6 or IL-10 was significantly increased in the peripheral blood cells of the rMV-EGFP controls at 3 days post challenge compared to those in rMV-TDV-immunized mice, which had no increase in inflammatory cytokines (p < 0.001). (Lin et al., 2020)
Description: YAC-CD46 mice, which carry the MV receptor-human CD46 transgene, were crossbred into AG129 mice to obtain AG-hCD46 transgenic mice (B6.129-Ifnar−/−, Ifngr−/− Tg(CD46)). (Lin et al., 2020)

21. TAK-003

a. Product Name:

DENVax

b. Type:

Live, attenuated vaccine

c. Status:

Clinical trial

d. Host Species for Licensed Use:

None

e. Antigen

whole virus (DENV2) and prM/E (serotypes 1 - 4) (Torres-Flores et al., 2022)

f. Preparation

(Torres-Flores et al., 2022)Tak-003/DENVax is based on a live-attenuated DENV-2 strain (PDK-53-V) in which the pre-membrane (prM) and envelope (E) genes of YFV have been replaced by the homologous genes from each one of the four DENV serotypes

g. Immunization Route

Intramuscular injection (i.m.)

h. Human Response

Vaccination Protocol: Healthy children and adolescents 4 to 16 years of age in regions of Asia and Latin America were randomly assigned in a 2:1 ratio (stratified according to age category and region) to receive two doses of vaccine or placebo 3 months apart. (Biswal et al., 2019)
Immune Response: Of the 20,071 participants who were given at least one dose of vaccine or placebo (safety population), 19,021 (94.8%) received both injections and were included in the per-protocol analysis. The overall vaccine efficacy in the safety population was 80.9% (95% confidence interval [CI], 75.2 to 85.3; 78 cases per 13,380 [0.5 per 100 person-years] in the vaccine group vs. 199 cases per 6687 [2.5 per 100 person-years] in the placebo group). In the per-protocol analyses, vaccine efficacy was 80.2% (95% CI, 73.3 to 85.3; 61 cases of virologically confirmed dengue in the vaccine group vs. 149 cases in the placebo group), with 95.4% efficacy against dengue leading to hospitalization (95% CI, 88.4 to 98.2; 5 hospitalizations in the vaccine group vs. 53 hospitalizations in the placebo group). Planned exploratory analyses involving the 27.7% of the per-protocol population that was seronegative at baseline showed vaccine efficacy of 74.9% (95% CI, 57.0 to 85.4; 20 cases of virologically confirmed dengue in the vaccine group vs. 39 cases in the placebo group). (Biswal et al., 2019)
Side Effects: The incidence of serious adverse events was similar in the vaccine group and placebo group (3.1% and 3.8%, respectively) (Biswal et al., 2019)

22. TV003/TV005

a. Manufacturer:

Laboratory of Infectious Diseases (LID) of the National Institute of Allergy and Infectious Diseases (NIAID)

b. Type:

Live, attenuated vaccine

c. Status:

Clinical trial

d. Host Species for Licensed Use:

None

e. Preparation

(Torres-Flores et al., 2022)TV003/TV005 was constructed by a deletion of 30 nucleotides (172–143) in the TL2 stem-loop of the 3′-UTR of DENV-4 and DENV-1 (rDEN4∆30 and rDEN1∆30), DENV-2 and DENV-3 components were constructed from the rDEN4∆30 backbone

f. Immunization Route

Intramuscular injection (i.m.)

g. Human Response

Vaccination Protocol: The lyophilized vaccine formulation was reconstituted before administration. One 0.5-ml dose of TAK-003 contained approximately 3.6, 4.0, 4.6, and 5.1 log10 plaque-forming units of TDV-1, TDV-2, TDV-3, and TDV-4, respectively. The placebo was a 0.5-ml injection of saline. Vaccine and placebo were administered subcutaneously into the upper arm (Biswal et al., 2019).
Immune Response: Against any serotype, efficacy was 80.2% in the per-protocol population (95% confidence interval [CI], 73.3 to 85.3; P<0.001; 61 cases of virologically confirmed dengue in the vaccine group and 149 in the placebo group).
For specific serotypes; efficacious for DENV-2,3, and 1. 97.7% efficacy against DENV-2, 73.7% efficacy against DENV-1, and 62.6% efficacy against DENV-3; Inconclusive against DENV-4.

The overall vaccine efficacy in the safety population was 80.9% (95% confidence interval [CI], 75.2 to 85.3; 78 cases per 13,380 [0.5 per 100 person-years] in the vaccine group vs. 199 cases per 6687 [2.5 per 100 person-years] in the placebo group) (Biswal et al., 2019).

23. V180 - Aluminum Hydroxide Alhydrogel™ Adjuvant

a. Type:

Subunit vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

None

d. Antigen

Truncated dengue envelope proteins (DEN-80E) for all 4 serotypes (Manoff et al., 2019)

e. Gene Engineering of E from Dengue virus 1

Type: Recombinant protein preparation
Description: Truncated versions of E consisting of the N-terminal portion of E (DEN-80E) for all 4 serotypes. (Manoff et al., 2019)
Detailed Gene Information: Click here.

f. Gene Engineering of E protein from Dengue Virus 2

Type: Recombinant protein preparation
Description: Truncated versions of E consisting of the N-terminal portion of E (DEN-80E) for all 4 serotypes. (Manoff et al., 2019)
Detailed Gene Information: Click here.

g. Gene Engineering of E from Dengue virus 3

Type: Recombinant protein preparation
Description: Truncated versions of E consisting of the N-terminal portion of E (DEN-80E) for all 4 serotypes. (Manoff et al., 2019)
Detailed Gene Information: Click here.

h. Gene Engineering of E from Dengue virus 4

Type: Recombinant protein preparation
Description: Truncated versions of E consisting of the N-terminal portion of E (DEN-80E) for all 4 serotypes. (Manoff et al., 2019)
Detailed Gene Information: Click here.

i. Immunization Route

Intramuscular injection (i.m.)

j. Description

A recombinant subunit Dengue Virus vaccine that utilizes 80% of the Envelope protein of all 4 serotypes as the antigen with aluminum hydroxide adjuvant.

k. Human Response

Vaccination Protocol: Among the 98 adults who were randomized into the trial, 57 (58%) were female, 92 (94%) were white, and the mean age was 27 years (range, 18 to 48 years). The gender, race/ethnicity, and age distributions were generally consistent across the treatment groups.The first, second, and third injections of trial product were received by 98 (100%), 94 (96%), and 90 (92%) of randomized participants, respectively. Overall, 83 (85%) participants completed the trial. (Manoff et al., 2019)
Immune Response: The medium-dose V180 formulation with Alhydrogel™ did not meet the pre-specified definition of a positive immune response, but showed limited evidence of immunogenicity for all 4 serotypes: SCRs ranged from 14.3 to 62.5%, while GMTs ranged from <10 to 20. For the medium-dose V180 formulation with Alhydrogel™, GMTs for some serotypes increased by Month 3, and then returned to baseline by Month 8 (6 Months Postdose 3).Tetravalent or ≥trivalent responses were exhibited by lower proportions of recipients of medium-dose V180 with Alhydrogel. (Manoff et al., 2019)
Side Effects: For all 4 treatment types, pain/tenderness was the most frequent injection-site AE, followed by erythema and swelling. Fever (temperature ≥38.0°C [100.4°F]) was reported in 0 (0%) Alhydrogel™ recipients. (Manoff et al., 2019)

24. V180 - ISCOMATRIX™ adjuvant

a. Type:

investigational recombinant subunit vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

None

d. Antigen

Truncated dengue envelope proteins (DEN-80E) for all 4 serotypes (Manoff et al., 2019)

e. Immunization Route

Intramuscular injection (i.m.)

f. Description

A recombinant subunit Dengue Virus vaccine that utilizes 80% of the Envelope protein of all 4 serotypes as the antigen with ISCOMATRIX™ adjuvant (Manoff et al., 2019).

g. Human Response

Vaccination Protocol: Among the 98 adults who were randomized into the trial, 57 (58%) were female, 92 (94%) were white, and the mean age was 27 years (range, 18 to 48 years). The gender, race/ethnicity, and age distributions were generally consistent across the treatment groups (data not shown).The first, second, and third injections of trial product were received by 98 (100%), 94 (96%), and 90 (92%) of randomized participants, respectively (Figure 1). Overall, 83 (85%) participants completed the trial. (Manoff et al., 2019)
Immune Response: Virus Neutralizing Antibody:

Each of the 6 V180 formulations containing ISCOMATRIX™ adjuvant met the pre-specified definition of a positive immune response, with seroconversion rates of ≥85.7% for all 4 dengue serotypes; GMTs ranged from 73 to 1344. Within each V180 dose level, GMTs were slightly higher (within 2-fold) for formulations with 60 ISCO™ units than formulations with 30 ISCO™ units. In contrast, for a given dose level of ISCOMATRIX™ adjuvant, GMTs did not increase with increasing doses of V180 antigen.

All 6 V180 formulations with ISCOMATRIX™ adjuvant had similar profiles: GMTs increased by Month 2 (28 Days Postdose 2), increased further by Month 3 (28 Days Postdose 3), and then declined over time through Month 14 (1 Year Postdose 3), remaining generally above baseline for DENV1, DENV2, and DENV3, and generally returning to baseline for DENV4. During long-term follow-up, GMTs generally remained higher in the 60 ISCO™ unit group than the 30 ISCO™ unit group for the low-dose V180 cohort, but tended to converge in the medium-dose and high-dose V180 cohorts.

Memory B-Cell Responses:

Induction of B-cell memory to each of the four DENV serotypes was observed in peripheral blood mononuclear cells among all participants who received 3 injections of high-dose V180 with ISCOMATRIX™ adjuvant (30 or 60 ISCO™ units) at 28 Days Postdose 3, the mean number of dengue-specific memory B cells in these recipients had increased in frequency by 1 to 2 logs over the pre-vaccination baseline

(Manoff et al., 2019)
Side Effects: V180 with ISCOMATRIX™ adjuvant was associated with a higher frequency of injection-site AEs (adverse effects) overall, injection-site AEs of erythema or swelling that were ≥5 cm or ≥10 cm, and a higher frequency of injection-site pain/tenderness that participants assessed as severe (defined in the protocol as the inability to do work or usual activities). V180 with ISCOMATRIX™ adjuvant was also associated with higher frequencies of systemic AEs overall, and those assessed by the investigator as related to study product. Fever (temperature ≥38.0°C [100.4°F]) was reported in 5 (9%) ISCOMATRIX™ adjuvant recipients.

(Manoff et al., 2019)

25. V180 - unadjuvanted

a. Type:

investigational recombinant subunit vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

None

d. Antigen

Truncated dengue envelope proteins (DEN-80E) for all 4 serotypes (Manoff et al., 2019)

e. Immunization Route

Intramuscular injection (i.m.)

f. Description

A recombinant subunit Dengue Virus vaccine that utilizes 80% of the Envelope protein of all 4 serotypes as the antigen (Manoff et al., 2019).

g. Human Response

Vaccination Protocol: Among the 98 adults who were randomized into the trial, 57 (58%) were female, 92 (94%) were white, and the mean age was 27 years (range, 18 to 48 years). The gender, race/ethnicity, and age distributions were generally consistent across the treatment groups. The first, second, and third injections of trial product were received by 98 (100%), 94 (96%), and 90 (92%) of randomized participants, respectively. Overall, 83 (85%) participants completed the trial. (Manoff et al., 2019)
Immune Response: Virus-Neutralizing Antibody:

The unadjuvanted high-dose V180 formulation did not meet the pre-specified definition of a positive immune response, but showed limited evidence of immunogenicity for all 4 serotypes: SCRs ranged from 14.3 to 62.5%, while GMTs ranged from <10 to 20. There was no detectable immune response in the unadjuvanted medium-dose V180 group or the placebo group. For the unadjuvanted high-dose V180 formulation, GMTs for some serotypes increased by Month 3, and then returned to baseline by Month 8 (6 Months Postdose 3). Tetravalent or ≥trivalent responses were exhibited by lower proportions of recipients of high-dose unadjuvanted V180, and by no recipients of medium-dose unadjuvanted V180. In the majority of instances when participants had FRNT50 titers ≥10 for only 3 seotypes, DENV4 was the serotype with a titer <10.

Memory B-Cell Responses:

The mean change ranged from a 0.4-log decrease to 1-log increase among recipients of unadjuvanted high-dose V180, and generally increased <1 log among placebo recipients.

(Manoff et al., 2019)
Side Effects: For all 4 treatment types, pain/tenderness was the most frequent injection-site AE, followed by erythema and swelling. Fever (temperature ≥38.0°C [100.4°F]) was reported in 0 (0%) unadujuvanted recipients. (Manoff et al., 2019)

V. References

1. Azevedo et al., 2011: Azevedo AS, Yamamura AM, Freire MS, Trindade GF, Bonaldo M, Galler R, Alves AM. DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III. PloS one. 2011; 6(7); e20528. [PubMed: 21779317].

2. Biswal et al., 2019: Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, Sirivichayakul C, Watanaveeradej V, Rivera L, Espinoza F, Fernando L, Dietze R, Luz K, Venâncio da Cunha R, Jimeno J, López-Medina E, Borkowski A, Brose M, Rauscher M, LeFevre I, Bizjajeva S, Bravo L, Wallace D. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents. The New England journal of medicine. 2019; 381(21); 2009-2019. [PubMed: 31693803].

3. Bray and Lai, 1991: Bray M, Lai CJ. Dengue virus premembrane and membrane proteins elicit a protective immune response. Virology. 1991; 185(1); 505-508. [PubMed: 1926792].

4. Chen et al., 2007: Chen L, Ewing D, Subramanian H, Block K, Rayner J, Alterson KD, Sedegah M, Hayes C, Porter K, Raviprakash K. A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques. Journal of virology. 2007; 81(21); 11634-11639. [PubMed: 17715224].

5. Costa et al., 2006: Costa SM, Paes MV, Barreto DF, PinhÃ£o AT, Barth OM, Queiroz JL, ArmÃ´a GR, Freire MS, Alves AM. Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence. Vaccine. 2006; 24(2); 195-205. [PubMed: 16122850].

6. Delenda et al., 1994: Delenda C, Frenkiel MP, Deubel V. Protective efficacy in mice of a secreted form of recombinant dengue-2 virus envelope protein produced in baculovirus infected insect cells. Archives of virology. 1994; 139(1-2); 197-207. [PubMed: 7826210].

7. Hadinegoro et al., 2015: Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cortés M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. The New England journal of medicine. 2015; 373(13); 1195-1206. [PubMed: 26214039].

8. Konishi et al., 2000: Konishi E, Yamaoka M, Kurane I, Mason PW. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine. 2000; 18(11-12); 1133-1139. [PubMed: 10590335].

9. Konishi et al., 2003: Konishi E, Terazawa A, Fujii A. Evidence for antigen production in muscles by dengue and Japanese encephalitis DNA vaccines and a relation to their immunogenicity in mice. Vaccine. 2003; 21(25-26); 3713-3720. [PubMed: 12922102].

10. Konishi et al., 2006: Konishi E, Kosugi S, Imoto J. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine. 2006; 24(12); 2200-2207. [PubMed: 16316713].

11. Lima et al., 2011: Lima DM, de Paula SO, FranÃ§a RF, Palma PV, Morais FR, Gomes-Ruiz AC, de Aquino MT, da Fonseca BA. A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection. Vaccine. 2011; 29(4); 831-838. [PubMed: 21115054].

12. Liu et al., 2006: Liu WT, Lin WT, Tsai CC, Chuang CC, Liao CL, Lin HC, Hung YW, Huang SS, Liang CC, Hsu HL, Wang HJ, Liu YT. Enhanced immune response by amphotericin B following NS1 protein prime-oral recombinant Salmonella vaccine boost vaccination protects mice from dengue virus challenge. Vaccine. 2006; 24(31-32); 5852-5861. [PubMed: 16759760].

13. Manoff et al., 2019: Manoff SB, Sausser M, Falk Russell A, Martin J, Radley D, Hyatt D, Roberts CC, Lickliter J, Krishnarajah J, Bett A, Dubey S, Finn T, Coller BA. Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults. Human vaccines & immunotherapeutics. 2019; 15(9); 2195-2204. [PubMed: 30427741].

14. Martina et al., 2009: Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clinical microbiology reviews. 2009; 22(4); 564-581. [PubMed: 19822889].

15. Porter et al., 1998: Porter KR, Kochel TJ, Wu SJ, Raviprakash K, Phillips I, Hayes CG. Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses. Archives of virology. 1998; 143(5); 997-991003. [PubMed: 9645204].

16. Ramanathan et al., 2009: Ramanathan MP, Kuo YC, Selling BH, Li Q, Sardesai NY, Kim JJ, Weiner DB. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes. Vaccine. 2009; 27(46); 6444-6453. [PubMed: 19580892].

17. Raviprakash et al., 2000: Raviprakash K, Porter KR, Kochel TJ, Ewing D, Simmons M, Phillips I, Murphy GS, Weiss WR, Hayes CG. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. The Journal of general virology. 2000; 81(Pt 7); 1659-1667. [PubMed: 10859370].

18. Raviprakash et al., 2001: Raviprakash K, Marques E, Ewing D, Lu Y, Phillips I, Porter KR, Kochel TJ, August TJ, Hayes CG, Murphy GS. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF. Virology. 2001; 290(1); 74-82. [PubMed: 11883007].

19. Raviprakash et al., 2006: Raviprakash K, Apt D, Brinkman A, Skinner C, Yang S, Dawes G, Ewing D, Wu SJ, Bass S, Punnonen J, Porter K. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology. 2006; 353(1); 166-173. [PubMed: 16814355].

20. Raviprakash et al., 2008: Raviprakash K, Wang D, Ewing D, Holman DH, Block K, Woraratanadharm J, Chen L, Hayes C, Dong JY, Porter K. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. Journal of virology. 2008; 82(14); 6927-6934. [PubMed: 18480438].

21. Thomas and Yoon, 2019: Thomas SJ, Yoon IK. A review of Dengvaxia®: development to deployment. Human vaccines & immunotherapeutics. 2019; 15(10); 2295-2314. [PubMed: 31589551].

22. Torres-Flores et al., 2022: Torres-Flores JM, Reyes-Sandoval A, Salazar MI. Dengue Vaccines: An Update. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2022; 36(3); 325-336. [PubMed: 35608749].

23. Villar et al., 2015: Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramírez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Miranda Montoya MC, Cortés Supelano M, Zambrano B, Langevin E, Boaz M, Tornieporth N, Saville M, Noriega F. Efficacy of a tetravalent dengue vaccine in children in Latin America. The New England journal of medicine. 2015; 372(2); 113-123. [PubMed: 25365753].

24. Wollner et al., 2021: Wollner CJ, Richner M, Hassert MA, Pinto AK, Brien JD, Richner JM. A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses. Journal of virology. 2021; 95(12); . [PubMed: 33762420].

25. Wu et al., 2003: Wu SF, Liao CL, Lin YL, Yeh CT, Chen LK, Huang YF, Chou HY, Huang JL, Shaio MF, Sytwu HK. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine. 2003; 21(25-26); 3919-3929. [PubMed: 12922127].